<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harry H Yoon, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1740225803"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancers of the upper gastrointestinal tract are highly lethal malignancies. Locally advanced, unresectable, and metastatic esophagogastric cancers are not curable, and the goals of therapy are symptom palliation and prolongation of survival. Palliative modalities for advanced esophagogastric cancer can be either local or systemic. While systemic therapy is the most effective treatment modality for patients with metastatic disease and it may adequately palliate dysphagia and other symptoms, such as nausea, pain, obstruction, perforation, or bleeding from a locally advanced or locally recurrent primary tumor, it often requires multidisciplinary management using endoscopic, surgical, radiotherapeutic, or other approaches. (See  <a class="medical medical_review" href="/d/html/2521.html" rel="external">"Local palliation for advanced gastric cancer"</a> and  <a class="medical medical_review" href="/d/html/2273.html" rel="external">"Endoscopic palliation of esophageal cancer"</a>.)</p><p>This topic review will cover initial systemic therapy for advanced, unresectable, and metastatic esophagogastric cancer. The choice of treatment for later lines of therapy for progressive, locally advanced, and metastatic disease; neoadjuvant strategies for locoregionally advanced but potentially resectable esophageal and gastric cancer; local methods for palliation in patients with advanced disease; and hepatic metastasectomy for the rare patient with isolated gastric cancer liver metastases are discussed separately. (See  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer"</a> and  <a class="medical medical_review" href="/d/html/2478.html" rel="external">"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"</a> and  <a class="medical medical_review" href="/d/html/2521.html" rel="external">"Local palliation for advanced gastric cancer"</a> and  <a class="medical medical_review" href="/d/html/2273.html" rel="external">"Endoscopic palliation of esophageal cancer"</a> and  <a class="medical medical_review" href="/d/html/2481.html" rel="external">"Surgical management of invasive gastric cancer", section on 'Metastasectomy'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">HISTOLOGY, ANATOMIC DISTRIBUTION, AND EVOLUTION OF CHEMOTHERAPY STRATEGY</span><span class="headingEndMark"> — </span>Together, squamous cell cancer (SCC) and adenocarcinoma account for 93 percent of all esophageal carcinomas, but histologic and anatomic distribution has changed dramatically over the past 30 years [<a href="#rid1">1</a>]. In the 1970s, SCC accounted for approximately 70 percent of all esophageal cancers, and 22 percent of tumors were located in the upper one-third of the thoracic esophagus or in the cervical esophagus. Since the mid-1970s, the incidence of SCC in the United States has been declining steadily, while the incidence of adenocarcinoma in White male patients rose by 350 percent from 1974 to 1994. Adenocarcinoma surpassed SCC as the dominant histology in the early 1990s [<a href="#rid2">2</a>]. At the same time, there has also been a shift in the location of esophageal cancers over time. At present, 86 percent of esophageal cancers arise in the distal one-third of the thoracic esophagus, 13 percent arise in the middle third, and only 1 percent arise in the upper third or cervical esophagus. (See  <a class="medical medical_review" href="/d/html/2274.html" rel="external">"Epidemiology and pathobiology of esophageal cancer"</a>.)</p><p>More than 90 percent of stomach cancers are adenocarcinomas. In 1930, most cases originated in the distal stomach (gastric body and antrum  (<a class="graphic graphic_figure graphicRef79793" href="/d/graphic/79793.html" rel="external">figure 1</a>)). Since then, the incidence of distal gastric carcinoma has declined dramatically, while the incidence of adenocarcinoma of the esophagogastric junction (EGJ) and proximal stomach has increased at a rate exceeding that of any other cancer [<a href="#rid3">3</a>]. The increasing incidence has paralleled the rise in incidence of esophageal adenocarcinoma. The term "EGJ tumor" reflects the frequent difficulty in separating the primary locations of distal esophageal and proximal gastric cancers; their natural history, response to therapy, and overall prognosis appear to be similar [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/2616.html" rel="external">"Epidemiology of gastric cancer"</a>.)</p><p>Chemotherapy drugs that were tested for esophageal cancer at a time when SCC was the predominant histology (1970s and 1980s) were those initially developed for SCC of the head and neck, including <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU), <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10303" href="/d/drug information/10303.html" rel="external">vindesine</a>, and <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. The combination of FU plus cisplatin was adopted by many as a safe and effective standard regimen, and studies focused on the benefit of adding a third agent to the FU plus cisplatin backbone.</p><p>At the other end of the spectrum, at a time when distal gastric adenocarcinomas were the most common stomach malignancy, most regimens for advanced gastric cancer were based on FU plus an anthracycline. Cisplatin-based combinations (such as <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and infusional FU) were eventually shown to be superior to non-cisplatin-containing regimens and became the reference regimens for advanced gastric cancer. (See <a class="local">'Epirubicin, cisplatin, and fluorouracil'</a> below.)</p><p>Coincident with the epidemiologic changes in histologic and anatomic distribution, the treatment of advanced gastric and esophageal cancers converged, and the majority of clinical trials conducted since the mid-1990s include patients with gastric, esophageal, or EGJ cancer, regardless of histology [<a href="#rid5">5,6</a>]. Although SCCs now represent a small minority of patients enrolled in most clinical trials, histologic subtype did not appear to play a major role in response rate or survival duration in patients treated with a variety of cytotoxic chemotherapy regimens for metastatic esophagogastric cancer [<a href="#rid7">7-12</a>].</p><p>However, this is changing as differences in genomic alterations in biologic pathways between SCC and adenocarcinoma are beginning to be elucidated [<a href="#rid13">13</a>]. Treatment for SCC and adenocarcinoma has diverged once again with the introduction of molecularly directed therapy and immunotherapy. Therapies targeting human epidermal growth factor receptor 2 (eg, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>) and vascular endothelial growth factor (eg, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>) are applicable only to adenocarcinomas. Immunotherapy approaches using immune checkpoint inhibitors appear to be effective for SCC regardless of programmed cell death ligand 1 (PD-L1) expression, whereas benefits in adenocarcinomas with low or absent PD-L1 expression are uncertain. (See <a class="local">'Choice of therapy'</a> below and  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Ramucirumab with or without paclitaxel'</a>.)</p><p class="headingAnchor" id="H2459828088"><span class="h1">OVERVIEW OF THE APPROACH TO FIRST-LINE THERAPY</span></p><p class="headingAnchor" id="H430161734"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goals of chemotherapy in patients with advanced esophagogastric cancer are to palliate symptoms (including malignant dysphagia), improve quality of life, and prolong survival. A number of controlled trials and meta-analyses provide evidence for the survival benefit of palliative systemic chemotherapy for patients with advanced gastric cancer [<a href="#rid14">14-20</a>]. In one meta-analysis of three trials comparing chemotherapy with best supportive care, there was a significant benefit in overall survival in favor of chemotherapy compared with supportive care alone (hazard ratio [HR] 0.3, 95% CI 0.24-0.55), which translated into an improvement in median survival from 4.3 to 11 months [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H676772337"><span class="h2">Early supportive care</span><span class="headingEndMark"> — </span>All patients with newly diagnosed advanced gastric cancer should have a full assessment of symptom burden, nutritional and psychologic status, and social supports as early as possible, ideally, prior to starting systemic chemotherapy. Many patients will benefit from formal palliative care consultation and services. Early referral and initiation of interdisciplinary and palliative care services improve clinical and quality of care outcomes, including survival. (See  <a class="medical medical_review" href="/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care", section on 'Rationale for palliative care'</a>.)</p><p>Because of the anatomy, and complications from surgery or local disease progression, patients with advanced esophagogastric cancer have a high incidence of malnutrition [<a href="#rid21">21,22</a>], and psychologic distress [<a href="#rid23">23,24</a>], both of which may impair survival.</p><p>Several therapeutic options are available to control symptoms of local disease progression (eg, nausea, pain, gastric outlet obstruction, bleeding), including palliative surgical resection, surgical bypass (gastrojejunostomy), radiation therapy (RT), and endoscopic techniques. Decision-making for local palliative therapy must take into account the overall prognosis of the patient in order to avoid excessive morbidity and mortality or lengthy hospital stays in those with a limited life span. (See  <a class="medical medical_review" href="/d/html/2521.html" rel="external">"Local palliation for advanced gastric cancer"</a>.)</p><p>The benefit of early interdisciplinary supportive care was shown in a trial in which 328 patients with previously untreated metastatic esophagogastric cancer were randomly assigned to early interdisciplinary care with a focus on nutrition and psychologic health integrated into standard oncologic care or standard care [<a href="#rid25">25</a>]. The intervention group received an interdisciplinary supportive care consultation within 14 days of initiating chemotherapy, and a follow-up consultation every three weeks thereafter. Median overall survival was significantly better in the early intervention group (14.8 versus 11.9, hazard ratio [HR] 0.68, 95% CI 0.51-0.9). Despite similar distribution, responses, and safety profiles of systemic therapy in the two groups, early supportive care also had a significant positive impact on emotional and cognitive functioning at week 9, and on the proportion of patients presenting with weight loss at week 9 (45 versus 58 percent).</p><p class="headingAnchor" id="H4031960416"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>We base our treatment decisions on biomarker expression and histology, as outlined in the following sections, and summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef129948" href="/d/graphic/129948.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H4160247156"><span class="h3">Biomarker assessment</span><span class="headingEndMark"> — </span>All patients with unresectable, locally advanced, recurrent, or metastatic esophagogastric adenocarcinoma who are potential candidates for <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> should have their tumors assayed for HER2 overexpression and/or gene amplification using specific criteria developed for esophagogastric adenocarcinomas. (See <a class="local">'Assessment of HER2 status and selection of candidates for trastuzumab'</a> below.)</p><p>In addition, all patients should have their tumors assayed for deficient mismatch repair/high levels of microsatellite instability (dMMR/MSI-H) and PD-L1 expression, with reporting out of individual expression levels (ie, combined positive score [CPS] 0 to 4, versus 5, versus 10 or more; or tumor proportion score [TPS] &gt;1 percent versus ≤1 percent). (See <a class="local">'PD-L1 expression status in upper GI tract cancers'</a> below.)</p><p>Biomarker assessment has become critically important for selecting the initial approach to systemic therapy, particularly for adenocarcinomas:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> is an active agent for first-line therapy, in combination with cytotoxic chemotherapy, for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing adenocarcinomas. (See <a class="local">'HER2-overexpressing adenocarcinomas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-line therapy with an immune checkpoint inhibitor in combination with chemotherapy improves outcomes over chemotherapy alone for patients with HER2-negative adenocarcinomas and high or intermediate programmed cell death ligand 1 (PD-L1) expression and those that are deficient in mismatch repair (dMMR). (See <a class="local">'HER2-negative adenocarcinoma'</a> below and <a class="local">'Deficient mismatch repair'</a> below.)</p><p></p><p class="bulletIndent1">First-line therapy with an immune checkpoint inhibitor has also been shown to improve outcomes over cytotoxic chemotherapy alone for patients with squamous cell cancers (SCCs). (See <a class="local">'Squamous cell cancers'</a> below.)</p><p></p><p>ASCO has issued a provisional clinical opinion that supports somatic genomic testing in metastatic or advanced cancer when there are genomic biomarker-linked therapies approved by regulatory agencies for their cancer [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2200887973"><span class="h3">Squamous cell cancer</span><span class="headingEndMark"> — </span>For advanced SCCs, we suggest first-line therapy with chemotherapy plus immunotherapy rather than chemotherapy alone for patients with PD-L1 TPS 1+ or CPS 10+. For patients with PD-L1 TPS &lt;1 percent or CPS &lt;10, we also suggest chemotherapy plus immunotherapy rather than chemotherapy alone, given the generally greater activity of immune checkpoint inhibitors in SCC as compared with adenocarcinomas and a meta-analysis that suggests a significant survival benefit in this population, albeit of a lesser magnitude than for those with higher PD-L1 expression. However, in such patients, we have a lower threshold to omit or discontinue immunotherapy in the presence of unfavorable baseline features (eg, CPS &lt;1, significant non-cancerous lung disease) or in those experiencing toxicity than we would in a patient with PD-L1 high disease given the likely lesser degree of efficacy in this population. (See <a class="local">'Squamous cell cancers'</a> below.)</p><p class="bulletIndent1">Although the chemotherapy backbone in CheckMate and KEYNOTE studies was <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU), many clinicians, including some of the authors and editors associated with this topic review, would prefer <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in combination with an oxaliplatin-based regimen such as <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> with bolus plus short-term FU (FOLFOX). Where available (mainly China), camrelizumab in combination with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and cisplatin is an appropriate alternative, as shown in the ESCORT-1<sup>st</sup> trial.</p><p></p><p class="headingAnchor" id="H750786067"><span class="h3">Adenocarcinomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HER2-overexpressing cancers</strong> – For patients with human epidermal growth factor receptor 2 (HER2)-overexpressing adenocarcinomas (as defined by 3+ immunohistochemistry staining or fluorescence in situ hybridization positivity), we suggest the addition of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> to a platinum-based cytotoxic chemotherapy backbone, as long as there is no contraindication to trastuzumab. Based upon the KEYNOTE-811 trial, we also suggest adding <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to initial trastuzumab plus platinum-based chemotherapy in these patients. (See <a class="local">'HER2-overexpressing adenocarcinomas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with deficient mismatch repair</strong> – For patients with dMMR/MSI-H tumors, most of which express PD-L1, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus cytotoxic chemotherapy rather than systemic chemotherapy alone. Pembrolizumab monotherapy is another option. (See <a class="local">'Deficient mismatch repair'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HER2-negative, PD-L1 positive, proficient MMR tumors</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥10</strong> – For most patients with HER2-negative adenocarcinoma and CPS ≥10, we suggest initial therapy with the addition of either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to an oxaliplatin-containing chemotherapy regimen (eg, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>) or XELOX/CAPOX  (<a class="graphic graphic_table graphicRef112347" href="/d/graphic/112347.html" rel="external">table 2</a>)) rather than chemotherapy alone, as this approach improved overall survival in randomized trials. (See <a class="local">'High PD-L1 expression'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS 5 to 9</strong> – For most patients with HER-2 negative adenocarcinomas and CPS of 5 to 9, we suggest initial therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus an oxaliplatin-containing chemotherapy regimen rather than chemotherapy alone. (See <a class="local">'Intermediate PD-L1 expression'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS &lt;5</strong> – For patients with CPS &lt;5, we suggest initial treatment with chemotherapy alone rather than immunotherapy plus chemotherapy. (See <a class="local">'Low or absent PD-L1 expression'</a> below.)</p><p></p><p class="headingAnchor" id="H2426133055"><span class="h2">Other adenocarcinomas and those without access to targeted therapy</span><span class="headingEndMark"> — </span>For individuals who are not receiving <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> or immunotherapy first-line either because they lack a molecular biomarker, or who have a contraindication, intolerance, or a lack of reimbursement, the choice of cytotoxic chemotherapy regimen is empiric: </p><p class="bulletIndent1"><span class="glyph">●</span>In general, combination chemotherapy regimens provide higher response rates than do single agents, but this translates into only modestly longer durations of disease control and survival (measured in weeks to a few months), and a worse side effect profile. (See <a class="local">'Combination chemotherapy'</a> below and <a class="local">'Is there an optimal combination regimen?'</a> below.)</p><p></p><p class="bulletIndent1">Participation in a clinical trial is preferred. If a trial is not available, or participation is not feasible, for most patients, we suggest a fluoropyrimidine-platinum doublet rather than a triplet regimen. For most patients, we prefer an oxaliplatin-containing regimen (ie, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>), <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, or where available, S-1 plus oxaliplatin). Other alternatives include FU plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (or where available, S-1 plus cisplatin). (See <a class="local">'Oxaliplatin combinations'</a> below.)</p><p></p><p class="bulletIndent1">For older patients or those with a poor performance status, appropriate alternatives include leucovorin-modulated FU alone, single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, single-agent <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, dose-attenuated capecitabine plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, or low-dose weekly taxanes. (See <a class="local">'Single-agent chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In our view, a role for first-line immune checkpoint inhibitor immunotherapy plus chemotherapy in PD-L1-negative adenocarcinomas is not yet proven, and this approach cannot be recommended. (See <a class="local">'Low or absent PD-L1 expression'</a> below.)</p><p></p><p class="headingAnchor" id="H1060451259"><span class="h2">Response assessment</span><span class="headingEndMark"> — </span>Response is assessed using a combination of interval radiographic evaluation (typically every two to three cycles); serum tumor markers, such as carcinoembryonic antigen (if elevated at baseline); and the clinical status of the patient. Radiographic tumor response is usually quantified using Response Evaluation Criteria in Solid Tumors  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 3</a>) [<a href="#rid27">27,28</a>].</p><p></p><p>If tumor markers are elevated at initial evaluation, they can be serially assessed during treatment as a surrogate measure of response to therapy. While persistently rising levels of a serum tumor marker suggest disease progression, this should be confirmed with radiologic studies prior to a change in therapeutic strategy. (See  <a class="medical medical_review" href="/d/html/2513.html" rel="external">"Clinical features, diagnosis, and staging of gastric cancer", section on 'Serologic markers'</a>.)</p><p>The patient's clinical status should always be taken into consideration in combination with radiologic and tumor marker data, where patients with clinical benefit from treatment may stay on that treatment regimen despite possible radiologic progression.</p><p class="headingAnchor" id="H832721689"><span class="h2">Treatment duration</span><span class="headingEndMark"> — </span>The duration of treatment in responding patients with advanced esophagogastric cancer has not been specifically studied. There are only limited data that pertain to discontinuation of a treatment regimen prior to disease progression or on modified maintenance therapy regimens. In one small randomized phase II trial that compared a "stop and go" strategy with continuous therapy following disease stabilization with first-line S-1 plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, patients who continued chemotherapy beyond disease stabilization had better progression-free survival (PFS; 10.5 versus 7.2 months); however, overall survival and the duration of disease control were not significantly better, and quality of life was worse [<a href="#rid29">29</a>].</p><p>In general, regimens are given until the patient has progressive disease or cannot tolerate further treatment with the regimen. We recommend that each patient's treatment plan be individualized depending on tolerance and response to the treatment regimen, as well as the patient's wishes as to treatment breaks or modifications.</p><p class="headingAnchor" id="H244586952"><span class="h1">EFFICACY OF INDIVIDUAL TREATMENTS</span></p><p class="headingAnchor" id="H1280072307"><span class="h2">Immunotherapy-based regimens</span></p><p class="headingAnchor" id="H3671968915"><span class="h3">PD-L1 expression status in upper GI tract cancers</span><span class="headingEndMark"> — </span>Checkpoint inhibitor immunotherapy has become a prominent and effective treatment for a variety of malignancies, but, with the exception of deficient mismatch repair (dMMR), the best way to identify the patients who are most likely to benefit is uncertain. (See <a class="local">'Deficient mismatch repair'</a> below.)</p><p>Programmed cell death ligand 1 (PD-L1) expression is the candidate biomarker that has been studied most extensively in trials utilizing immunotherapy that relies on programmed cell death-1 (PD-1) blockade. PD-L1 and PD-1 expression are dynamic markers that change in relation to local cytokines and other factors. Although expression of PD-L1 exists along a continuum, the thresholds that separate "positive" and "negative" PD-L1 expression remain under debate. Nevertheless, most modern trials use prespecified cutpoints, in part because compared with continuous values, the inter-pathologist agreement appears to be high [<a href="#rid30">30</a>].</p><p>Most trials with either retrospective or prospective assessments of PD-L1 status have shown trends for increased response rates to PD-1 blockade in PD-L1 "positive" tumors, as defined by prespecified cutpoints, across a variety of malignancies [<a href="#rid31">31-34</a>]. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Predictors of response to immune-based therapy'</a>.)</p><p>PD-L1 expression is used as a diagnostic marker in other malignancies, including upper gastrointestinal malignancies. However, the available data has been mixed. The lack of benefit for checkpoint inhibitor immunotherapy in those with low or absent PD-L1 expression has been most clearly demonstrated for adenocarcinomas, while the situation for squamous cell cancers (SCCs) is evolving. Initially, results from the CheckMate 648, KEYNOTE-590, and ESCORT-1st trials suggested benefit for all SCC subgroups, regardless of PD-L1 expression. These data led the US Food and Drug Administration (FDA) to approve <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the treatment of metastatic or locally advanced esophageal or esophagogastric junction (EGJ) carcinomas (including adenocarcinoma) with an epicenter 1 to 5 cm above the EGJ and who were not eligible for resection or chemoradiation, regardless of PD-L1 expression. However, updated analysis of the Checkmate 648 trial suggests no benefit for the addition of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> to cytotoxic chemotherapy in esophageal SCC with a tumor proportion score (TPS) &lt;1 percent [<a href="#rid35">35</a>]. (See <a class="local">'Squamous cell cancers'</a> below.)</p><p>There are three questions that commonly arise in this area:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is the interchangeability of the assays used to assess PD-L1 expression for </strong><strong>nivolumab</strong><strong> versus </strong><strong>pembrolizumab</strong><strong>?</strong></p><p></p><p class="bulletIndent1">The 22C3 PharmDx IHC assay is the only FDA-approved companion diagnostic assay for assessing the safety and effectiveness of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in a variety of malignancies, including gastric or EGJ adenocarcinoma and esophageal SCC [<a href="#rid36">36</a>]. By contrast, the PD-L1 28-8 PharmDx assay is the approved complementary diagnostic assay for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>. The best comparison data indicate that the agreement between these two assays in gastric cancer at a combined positive score (CPS) cutpoint of 1 and 10 was 96 percent [<a href="#rid37">37</a>], suggesting that they are interchangeable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is the best method to score PD-L1 expression in formalin-fixed, paraffin-embedded tissue?</strong></p><p></p><p class="bulletIndent1">The regulatory approval of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for treatment of gastric and EGJ adenocarcinomas required a reproducible scoring method for use of PD-L1 protein expression as a companion diagnostic to identify likely responders to therapy. In tumors other than gastric cancer (eg, non-small cell lung cancer), the TPS (ie, the number of PD-L1-stained tumor cells divided by the total number of viable tumor cells and multiplied by 100) has been shown to identify those patients with PD-L1+ tumors who are likely to respond to pembrolizumab, but immune cell PD-L1 expression is also important. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'PD-L1-high tumors (at least 50 percent)'</a>.)</p><p></p><p class="bulletIndent1">The CPS is the total number of PD-L1 stained cells (including tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells and multiplied by 100. It is a robust reproducible PD-L1 scoring method that predicts a response to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in gastric and EGJ cancer with inter-pathologist and intra-pathologist agreement of 97 percent, and inter-institution agreement of 92 percent [<a href="#rid30">30</a>]. This is the preferred approach. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Diagnostic tests'</a>.)</p><p></p><p class="bulletIndent1">Nevertheless, some contemporary trials have used TPS. There are few data correlating CPS and TPS. In the CheckMate 648 trial of combined immunotherapy plus chemotherapy versus chemotherapy alone in advanced SCC, a TPS cutpoint of ≥1 percent seemed to identify a population whose survival with combined therapy was comparable to that of those treated at a CPS cutpoint of ≥10 percent [<a href="#rid35">35</a>], although the correlation between TPS and CPS remains unknown. (See <a class="local">'Squamous cell cancers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there temporospatial heterogeneity of PD-L1 expression within and between tumor sites, and is rebiopsy indicated?</strong></p><p></p><p class="bulletIndent1">Heterogeneity of PD-L1 expression within individual tumors and between tumor sites has been described for multiple cancer types. Within upper gastrointestinal tract tumors, PD-L1 expression displays marked spatial heterogeneity between baseline primary tumors and metastases (69 percent concordance in one study [<a href="#rid38">38</a>]) and temporal heterogeneity between tumors before and after chemotherapy (73 to 75 percent concordance in the same study). In comparisons between paired baseline primary and baseline metastatic tumors (spatial heterogeneity), only 42 percent of CPS 1+ primaries had corresponding CPS ≥1 metastases (the metastases for other patients were CPS &lt;1). By contrast, 88 percent of individuals with CPS &lt;1 primaries had CPS &lt;1 metastases. Findings were similar for CPS at the cutpoint of ≥10. These data provide an argument against empiric use of ICIs in gastric cancer.</p><p></p><p class="bulletIndent1">The issue of temporal heterogeneity raises the question as to whether tumors should be rebiopsied. In this regard, 64 percent of tumors in this analysis that were PD-L1 CPS ≥1 at baseline stayed positive post-treatment, whereas 39 percent of PD-L1 CPS &lt;1 tumors "became" CPS ≥1 posttreatment. But for CPS &lt;10 at baseline, posttreatment biopsy was CPS ≥10 only 17 percent of the time. It is not uncommon in clinical practice to see initially PD-L1-negative tumors "become" PD-L1-positive after treatment. As a result, we tend to repeat biopsy when possible, especially if CPS is absent/low, but this is not yet a standard approach, and there is no strong evidence that this improves outcomes. A major caveat is that it is not known whether "chemo-induced" PD-L1 expression has the same biologic implication as "native" PD-L1 expression.</p><p></p><p class="bulletIndent1">Additional studies are needed to determine the optimal location and timing for measurement of these biomarkers, and this issue is under active study [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H3674506301"><span class="h3">HER2-negative adenocarcinoma</span></p><p class="headingAnchor" id="H609244643"><span class="h4">High PD-L1 expression</span><span class="headingEndMark"> — </span>For most patients with HER2-negative adenocarcinoma and CPS ≥10 (ie, high PD-L1 expression), we suggest the addition of either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to an oxaliplatin-containing chemotherapy regimen (eg, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>) or XELOX/CAPOX  (<a class="graphic graphic_table graphicRef112347" href="/d/graphic/112347.html" rel="external">table 2</a>)) rather than systemic chemotherapy alone, as this approach improved overall survival (OS) in randomized trials (CheckMate 649 [<a href="#rid40">40,41</a>] and KEYNOTE-859 [<a href="#rid42">42</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>fluorouracil</strong><strong> and </strong><strong>oxaliplatin</strong> – <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> plus oxaliplatin-based chemotherapy is an option for patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic gastric or gastroesophageal adenocarcinoma and CPS ≥5. The recommended nivolumab doses in combination with chemotherapy are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>360 mg every three weeks in combination with every three-week chemotherapy (eg, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>240 mg every two weeks in combination with every two-week chemotherapy (eg, FOLFOX)</p><p></p><p class="bulletIndent1">In an open-label phase III trial (CheckMate 649), 1581 patients with previously untreated HER2-negative, advanced/unresectable or metastatic gastric, EGJ, or esophageal adenocarcinoma were randomly assigned to either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (360 mg every three weeks or 240 mg every two weeks) plus chemotherapy or chemotherapy alone [<a href="#rid40">40,41</a>]. Chemotherapy regimens were <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus either <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU; FOLFOX) or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (XELOX; also known as CAPOX). Although patients were enrolled regardless of PD-L1 expression, the CPS was ≥5 in 955 patients (60 percent). At median follow-up of approximately 13 months, compared with chemotherapy alone, nivolumab plus chemotherapy demonstrated the following results [<a href="#rid41">41</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Entire study population</strong> – Improved OS (median 13.8 versus 11.6 months; two-year OS 28 versus 19 percent, hazard ratio [HR] 0.79, 95% CI 0.71-0.88; two-year OS 28 versus 19 percent) and progression-free survival (PFS; median 7.7 versus 6.9 months; two-year PFS 16 versus 10 percent, HR 0.79, 95% CI 0.70-0.89). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥5</strong> – Improved OS (median 14.4 versus 11.1 months; two-year OS 31 versus 19 percent, HR 0.70, 95% CI 0.61-0.81) and PFS (median 8.1 versus 6.1 months; two-year PFS 19 versus 11 percent, HR 0.70, 95% CI 0.60-0.81). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other CPS subgroups</strong> – In an unplanned subgroup analysis, there was no overall survival benefit for those with CPS &lt;1 (median overall survival 13.1 versus 12.5 months, unstratified HR 0.95, 95% CI 0.73-1.24), CPS &lt;5 (median overall survival 12.4 versus 12.3 months, unstratified HR 0.94, 95% CI 0.79-1.11), or CPS &lt;10 (median 12.4 versus 12.5 months, HR 0.91, 95% CI 0.78-1.06). Interaction analysis of overall survival by PD-L1 CPS cutoffs was not provided.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxicity</strong> – More frequent grade ≥3 treatment-related adverse events (59 versus 44 percent), treatment discontinuation for toxicity (17 versus 9 percent), and treatment-related deaths (17 versus 9 patients, 2 versus &lt;1 percent).</p><p></p><p class="bulletIndent1">Based on initial reports of these data [<a href="#rid40">40</a>], <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was approved by the FDA, in combination with a fluoropyrimidine and platinum-containing regimen, for advanced or metastatic gastric and gastroesophageal junction cancer and esophageal adenocarcinoma irrespective of PD-L1 expression [<a href="#rid43">43</a>]. However, in our view, the benefits of immunotherapy for adenocarcinomas with low or absent PD-L1 expression (ie, CPS &lt;5) are not established. Notably, the European Medicines Agency (EMA) has restricted approval of nivolumab to those with PD-L1 CPS ≥5 [<a href="#rid44">44</a>]. Further details are discussed separately. (See <a class="local">'Low or absent PD-L1 expression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus </strong><strong>fluorouracil</strong><strong> and platinum</strong> – <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> plus oxaliplatin-based chemotherapy is another initial treatment option for patients with HER2-negative metastatic gastric or gastroesophageal adenocarcinoma and CPS ≥10  (<a class="graphic graphic_algorithm graphicRef129948" href="/d/graphic/129948.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent1">In a double-blind, placebo-controlled phase III trial (KEYNOTE-859), the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to chemotherapy improved OS and PFS [<a href="#rid42">42</a>]. In this study, 1579 patients with previously untreated HER2-negative, locally advanced or metastatic gastric (79 percent) or gastroesophageal junction (21 percent) adenocarcinoma were randomly assigned to the addition of either pembrolizumab (200 mg intravenously every three weeks for up to 35 cycles) or placebo to investigator's choice of chemotherapy (either <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or CAPOX). At median follow-up of 31 months, data were as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Entire study population</strong> – <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> plus chemotherapy improved OS (median 12.9 versus 11.5 months, HR 0.78, 95% CI 0.70-0.87), PFS (median 6.9 versus 5.6 months, HR 0.76, 95% CI 0.67-0.85) and objective response rates (51 versus 42 percent) over placebo plus chemotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High CPS and MSI-H tumors</strong> – OS and PFS benefits for the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy were consistent across subgroups, including those with CPS ≥1 (HR 0.74, 95% CI 0.65-0.84 for OS; HR 0.72, 95% 0.63-0.82 for PFS), CPS ≥10 (HR 0.65, 95% CI 0.53-0.79 for OS; HR 0.62, 95% CI 0.51-0.76 for PFS), and those with high levels of microsatellite instability (MSI-H) tumors (HR 0.34, 95% CI 0.18-0.66 for OS, HR 0.27, 95% CI 0.14-0.53 for PFS). (See <a class="local">'Deficient mismatch repair'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxicity</strong> – Grade ≥3 toxicity rates for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy and placebo plus chemotherapy were 60 versus 51 percent, respectively. </p><p></p><p class="bulletIndent1">In a separate phase III trial (KEYNOTE-062) of patients with HER2-negative gastric or gastroesophageal adenocarcinoma, the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to chemotherapy did not improve OS or PFS for those with CPS ≥1 or OS for those with CPS ≥10 [<a href="#rid45">45</a>]. However, pembrolizumab plus chemotherapy and pembrolizumab monotherapy did benefit the subset of patients with both positive PD-L1 expression and dMMR/MSI-H. These data are discussed separately. (See <a class="local">'Deficient mismatch repair'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for</strong> <strong>pembrolizumab</strong><strong> monotherapy? </strong>–<strong> </strong>We do not typically offer initial therapy with single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> outside of a clinical trial, including to patients whose tumors have CPS ≥10. In an exploratory analysis of a randomized trial (KEYNOTE-062), pembrolizumab alone prolonged OS relative to chemotherapy alone in patients whose tumors had a CPS ≥10, but this difference was not statistically tested. In addition, these and other data also suggest that patients who receive either immunotherapy alone (either as monotherapy or combination therapy [ie, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>]) are at risk for worse PFS (ie, early disease progression or death) [<a href="#rid41">41,45</a>]. </p><p></p><p class="bulletIndent1">In a phase III KEYNOTE-062 trial, 763 patients with previously untreated, advanced, gastric or EGJ adenocarcinoma with a CPS ≥1 (281 with a CPS ≥10) were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> alone, chemotherapy alone (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus a fluoropyrimidine), or pembrolizumab plus chemotherapy [<a href="#rid45">45</a>]. At a median follow-up of approximately 29 months, data were as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥1</strong> – For patients with CPS ≥1, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy compared with chemotherapy demonstrated noninferior, but not superior, OS (median 10.6 versus 11.1 months, hazard ratio [HR] 0.91, 99% CI 0.69-1.18), worsened PFS (median 2.0 versus 6.4 months, HR 1.66, 95% CI 1.37-2.01) and lower objective response rate (15 versus 37 percent). Pembrolizumab had fewer any-grade (54 versus 92 percent) and grade 3 or 4 (17 versus 69 percent) adverse effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CPS ≥10</strong> – In an exploratory analysis of patients with CPS ≥10, compared with chemotherapy alone, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy prolonged OS, although this was not statistically tested (median 17.4 versus 10.8 months, HR 0.69, 95% CI 0.49-0.97) and demonstrated a non-statistically significant trend towards lower PFS (median 2.9 versus 6.1 months, HR 1.10, 95% CI 0.79-1.51).</p><p></p><p class="headingAnchor" id="H1681769094"><span class="h4">Intermediate PD-L1 expression</span><span class="headingEndMark"> — </span>For most patients with HER-2 negative adenocarcinomas and CPS 5 to 9 (ie, intermediate PD-L1 expression), we suggest initial therapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus an oxaliplatin-containing chemotherapy regimen rather than chemotherapy alone.</p><p>Data are limited for the benefits of combining immunotherapy and chemotherapy in patients with a CPS of 5 to 9. In addition, this combination is associated with additional toxicity and cost. Further data are needed that specifically evaluate adding immunotherapy to chemotherapy within this subgroup. </p><p>In one phase III trial (CheckMate 649), for the subgroup with CPS ≥5, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy improved OS versus chemotherapy alone [<a href="#rid41">41</a>]. </p><p>Another phase III trial (KEYNOTE-859) demonstrated an OS benefit for adding <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to chemotherapy among those with CPS ≥1. However, it is not established if the OS benefit is being meaningfully driven by those with CPS between 5 and 9 [<a href="#rid46">46</a>]. Further results of these trials are discussed separately. (See <a class="local">'High PD-L1 expression'</a> above.)</p><p>Other randomized trials have also failed to demonstrate an overall survival benefit for adding immunotherapy (either <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) to chemotherapy in patients with advanced gastric or gastroesophageal adenocarcinoma and CPS &lt;10  (<a class="graphic graphic_table graphicRef135164" href="/d/graphic/135164.html" rel="external">table 4</a>). However, specific OS data for those with CPS between 5 and 9 are not reported. </p><p class="headingAnchor" id="H4027113715"><span class="h4">Low or absent PD-L1 expression</span><span class="headingEndMark"> — </span>For patients with CPS &lt;5 (ie, low or absent PD-L1 expression), we suggest initial treatment with chemotherapy alone rather than immunotherapy plus chemotherapy. Several randomized trials have demonstrated limited benefit for adding immunotherapy to chemotherapy as initial treatment of advanced esophagogastric adenocarcinoma with low or absent PD-L1 expression. Patients with dMMR/MSI-H disease are discussed separately. (See <a class="local">'Deficient mismatch repair'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>KEYNOTE-590</strong> – In the first analysis of the phase III KEYNOTE-590 trial, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus chemotherapy significantly improved survival over chemotherapy alone in a combined population of previously untreated advanced/unresectable or metastatic esophageal adenocarcinoma, esophageal squamous cell carcinoma, or EGJ Siewert type 1 adenocarcinoma regardless of PD-L1 expression [<a href="#rid47">47</a>]. However, adenocarcinomas formed a minority of the study population (27 percent), and the results were driven more by SCC than by adenocarcinoma. When stratified according to level of PD-L1 expression, benefit was exclusively seen in the population with CPS ≥10 (median survival 13.5 versus 9.4 months in the pooled population of both adenocarcinoma and SCC; HR 0.62, 95% CI 0.49-0.78). There did not seem to be a benefit for adding pembrolizumab in those with CPS &lt;10 (median survival 10.5 versus 10.6 months, HR 0.86, 95% CI 0.68-1.10). Furthermore, the results were driven more by SCC (median survival 13.9 versus 8.8 months, HR 0.57, 95% CI 0.43-0.75) than by adenocarcinomas (median OS 11.6 versus 9.9 months, HR 0.74, 95% CI 0.54-1.02). (See <a class="local">'Squamous cell cancers'</a> below.)</p><p></p><p class="bulletIndent1">Largely based upon these initial data, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the treatment of patients with metastatic or locally advanced esophageal or EGJ carcinoma (including adenocarcinoma) with an epicenter 1 to 5 cm above the EGJ who are not eligible for resection or chemoradiation, regardless of PD-L1 expression [<a href="#rid48">48</a>]. However, in our view, the benefits of immunotherapy for adenocarcinomas with low-level or no expression of PD-L1 remain uncertain. Although opinion differs, especially with regard to CPS 1 to 4, we suggest initial chemotherapy rather than immunotherapy in these patients, unless they have dMMR/MSI-H tumors. This position is consistent with the EMA approval of pembrolizumab for esophageal cancer, which is restricted to those with a PD-L1 CPS ≥10 [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">This position is supported by a combined analysis of data from CheckMate 649, KEYNOTE-062, and KEYNOTE-059, which concluded that there was a lack of benefit for the addition of an immune checkpoint inhibitor to chemotherapy in gastroesophageal adenocarcinomas with low or absent PD-L1 expression [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Further support for this stance is provided by an updated analysis of KEYNOTE-590 with median follow-up 34.8 months, which continued to show a significant survival benefit from the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to chemotherapy in the combined population (median 12.4 versus 9.8 months, HR 0.73, 95% CI 0.63-0.86) and in preplanned subgroups of those with PD-L1 CPS ≥10 (median 13.6 versus 9.4 months, HR 0.64, 95% CI 0.51-0.80), and adenocarcinomas (median 11.6 versus 9.9 months, HR 0.73, 95% CI 0.55-0.99) [<a href="#rid51">51</a>]. Unplanned subgroup analysis suggested no significant benefit for the addition of pembrolizumab to chemotherapy for subgroups with CPS &lt;10 regardless of histology (HR 0.84, 95% CI 0.67-1.06), but a test for interaction was not provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ATTRACTION-4</strong> – Data are also available from the randomized phase III ATTRACTION-4 trial, in which 724 Asian patients with HER2-negative advanced or recurrent gastric or EGJ adenocarcinoma were randomly assigned to chemotherapy (<a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus either S-1 or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>) plus placebo, or the same chemotherapy plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (360 mg) every three weeks until disease progression or unacceptable toxicity [<a href="#rid52">52</a>]. At a median follow-up of 11.6 months (interim analysis), median PFS was significantly improved with combined therapy (10.5 versus 8.3 months, HR 0.68, 95% CI 0.51-0.90). However, the OS analysis, which was conducted with a later data cutoff point (at a median follow-up of 26.6 months), showed only a trend toward better median OS (17.5 versus 17.2 months, HR 0.90, 95% CI 0.75-1.08). Notably, 27 percent of the patients in the control arm received poststudy treatment with an anti-PD-1 agent. The addition of immunotherapy to chemotherapy also did not confer an OS benefit among those with TPS ≥1 percent; however, TPS may not be as predictive as CPS for PD-L1 expression in upper gastrointestinal tract adenocarcinomas [<a href="#rid53">53</a>]. (See <a class="local">'PD-L1 expression status in upper GI tract cancers'</a> above.)</p><p></p><p class="headingAnchor" id="H1645775979"><span class="h3">Squamous cell cancers</span></p><p class="headingAnchor" id="H328107269"><span class="h4">Efficacy versus chemotherapy alone</span><span class="headingEndMark"> — </span>For patients with advanced SCCs and PD-L1 TPS ≥1 percent or CPS ≥10, we suggest first-line therapy with chemotherapy plus immunotherapy rather than chemotherapy alone.</p><p>For patients with SCC and PD-L1 TPS &lt;1 percent or CPS &lt;10, we also suggest chemotherapy plus immunotherapy rather than chemotherapy alone, given the generally greater activity of immune checkpoint inhibitors in SCC as compared with adenocarcinomas and meta-analysis data that suggest a significant survival benefit in this population, albeit of a lesser magnitude than for those with high PD-L1 expression [<a href="#rid54">54</a>]. However, for patients whose tumors express low or absent levels of PD-L1, we have a lower threshold to omit or discontinue immunotherapy in the presence of unfavorable baseline features (eg, CPS &lt;1, significant non-cancerous lung disease, experiencing toxicity) than we would in a patient with PD-L1 high disease given the likely lesser degree of efficacy in this population.</p><p>We do not favor immunotherapy alone in tumors that have low PD-L1 expression due to concerns about early progression/death compared with chemotherapy alone [<a href="#rid35">35,41,45,55</a>]. Because of this concern, we restrict the use of immunotherapy alone (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>) to patients with TPS ≥1 percent disease.</p><p>Support for upfront immunotherapy in esophageal SCCs is provided by the CheckMate 648 study (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, an immune checkpoint inhibitor that targets a different checkpoint, cytotoxic T-lymphocyte-associated protein 4 [CTLA4]), by the KEYNOTE-590 trial (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus fluorouracil and cisplatin), by the ESCORT-1<sup>st</sup> trial (camrelizumab plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and cisplatin), ORIENT-15 trial (sintilimab plus paclitaxel and cisplatin), and JUPITER-06 (<a class="drug drug_general" data-topicid="143227" href="/d/drug information/143227.html" rel="external">toripalimab</a> plus paclitaxel and cisplatin) trials. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Checkpoint inhibitor immunotherapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CheckMate 648</strong> – In the CheckMate 648 trial, 970 adults with previously untreated, advanced unresectable, recurrent, or metastatic esophageal SCC regardless of PD-L1 expression were randomly assigned to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (240 mg every two weeks) plus chemotherapy (<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [800 mg/m<sup>2</sup> daily, days 1 through 5] plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [80 mg/m<sup>2</sup> on day 1] every four weeks), nivolumab (3 mg/kg every two weeks) plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (1 mg/kg every six weeks), or chemotherapy alone [<a href="#rid35">35</a>]. Overall 49 percent of the randomized patients had tumor cell PD-L1 ≥1 percent.</p><p></p><p class="bulletIndent1">Patients receiving <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy had a significantly longer median overall survival compared with chemotherapy alone in both the entire population (13.2 versus 10.7 months, HR 0.74, 95% CI 0.58-0.96) and in those with PD-L1 ≥1 percent according to the TPS (15.4 versus 9.1 months, HR 0.54, 95% CI 0.37-0.80). Patients receiving nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> also had a statistically significant overall survival benefit compared with chemotherapy alone in both the entire population (12.7 versus 10.7 months, HR 0.78, 95% CI 0.62-0.98) as well as in those with PD-L1 ≥1 percent (13.7 versus 9.1 months, HR 0.64, 95% CI 0.46-0.90). When the analysis was done according to CPS rather than TPS, among those with a CPS of 1 or more (824 of 906 patients), overall survival still favored nivolumab plus chemotherapy versus chemotherapy alone (median 13.8 versus 9.8 months). The best outcomes from combined therapy seemed to occur in those with either TPS ≥1 or CPS ≥10.</p><p></p><p class="bulletIndent1">Objective response rates were highest in the group receiving <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy, followed by nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, and then chemotherapy alone (53, 35, and 20 percent, respectively).</p><p></p><p class="bulletIndent1">Among the subset of patients with tumor cell PD-L1 expression of &lt;1 percent by TPS, the median overall survival was approximately 12 months in each treatment group (HR for the comparison of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy versus chemotherapy alone 0.92), and no PFS benefit was apparent with the nivolumab plus chemotherapy regimens compared with chemotherapy alone. Among those with a CPS of &lt;1, median overall survival was 9.9 months with nivolumab plus chemotherapy versus 12.1 months with chemotherapy alone.</p><p></p><p class="bulletIndent1">Rates of severe adverse effects were similar with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>/<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and chemotherapy alone (32 and 36 percent, respectively, with fewer than 20 percent of the patients in each group discontinuing therapy because of side effects), and slightly higher in the group receiving nivolumab plus chemotherapy (47 percent, with 34 percent resulting in treatment discontinuation), possibly because of the longer duration of therapy in this group (5.7 months, as compared with 2.8 and 3.4 months for the ipilimumab/nivolumab and chemotherapy alone, respectively).</p><p></p><p class="bulletIndent1">The authors concluded that <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy or <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> offered improved outcomes over chemotherapy alone in advanced previously untreated esophageal SCC. In our view, this trial demonstrated better overall and PFS as well as higher response rates and a longer duration of therapy with nivolumab plus chemotherapy versus nivolumab plus ipilimumab, and we generally favor nivolumab plus chemotherapy over nivolumab plus ipilimumab.</p><p></p><p class="bulletIndent1">Largely based on these results, in May 2022, the FDA approved <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, in combination with either platinum plus fluoropyrimidine-based chemotherapy or <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, for first-line treatment of patients with advanced or metastatic esophageal SCC, regardless of PD-L1 expression [<a href="#rid56">56,57</a>]. However, whether the addition of immunotherapy to chemotherapy benefits individuals with low PD-L1 expression is a controversial issue. Notably, the EMA restricts approval of nivolumab to esophageal SCCs with PD-L1 expression TPS ≥1 percent [<a href="#rid54">54</a>]. This issue is discussed in detail below. (See <a class="local">'Low PD-L1 expression (squamous cell carcinoma)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>KEYNOTE-590</strong> – Additional support is provided by the phase III KEYNOTE-590 trial that randomly assigned 749 patients with previously untreated advanced/unresectable or metastatic esophageal adenocarcinoma, esophageal SCC, or EGJ Siewert type 1 adenocarcinoma regardless of PD-L1 expression to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (200 mg every three weeks for up to 35 cycles) plus chemotherapy (FU 800 mg/m<sup>2</sup> IV days 1 through 5 every three weeks for up to 35 cycles), and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (80 mg/m<sup>2</sup> IV every three weeks for up to 6 cycles), or the same schedule of chemotherapy alone [<a href="#rid47">47</a>]. The primary endpoints were overall survival and PFS. In an interim analysis at a median follow-up of 22.6 months, median survival was significantly better with combined therapy (12.4 versus 9.8 months, HR 0.73, 95% CI 0.62-0.86), as was median PFS (6.3 versus 5.8 months, HR 0.65, 95% CI 0.55-0.76). The confirmed objective response rate was higher with combined therapy (45 versus 29 percent), with a median duration of response of 8.3 versus 6.0 months, and the incidence rates of grade 3 to 5 drug-related adverse events were 86 versus 83 percent.</p><p></p><p class="bulletIndent1">There are two significant provisos to these data:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When stratified according to PD-L1 expression, benefit was exclusively seen in the population with CPS ≥10 (median survival 13.5 versus 9.4 months in the pooled population of both adenocarcinoma and SCC; HR 0.62, 95% CI 0.49-0.78). There did not seem to be a benefit for adding <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in those with CPS &lt;10 (median survival 10.5 versus 10.6 months, HR 0.86, 95% CI 0.68-1.10).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The results were driven more by SCC (median survival 13.9 versus 8.8 months, HR 0.57, 95% CI 0.43-0.75) than by adenocarcinomas (median overall survival 11.6 versus 9.9 months, HR 0.74, 95% CI 0.54-1.02), which formed a minority of the study population (27 percent). However, even among those with SCC the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> did not benefit those with CPS &lt;10 (n = 247 patients, HR for overall survival 0.99, 95% CI 0.74-1.32).</p><p></p><p class="bulletIndent1">In a later analysis of KEYNOTE-590 with median follow-up 34.8 months continued to show a significant survival benefit from the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to chemotherapy in the combined population (median 12.4 versus 9.8 months, HR 0.73, 95% CI 0.63-0.86) and, in preplanned subgroups of those with PD-L1 CPS ≥10 (median 13.6 versus 9.4 months, HR 0.64, 95% CI 0.51-0.80), SCC (median 12.6 versus 9.8 months, HR 0.73, 95% CI 0.61-0.88), SCC and PD-L1 ≥10 (median 13.9 versus 8.8 months, HR 0.59, 95% CI 0.45-0.76) [<a href="#rid51">51</a>]. Unplanned subgroup analysis suggested no significant benefit for the addition of pembrolizumab to chemotherapy for any subgroup with CPS &lt;10 (HR 0.84, 95% CI 0.67-1.06), but a test for interaction was not provided.</p><p></p><p class="bulletIndent1">Nevertheless, largely based on the first analysis of KEYNOTE-590, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the treatment of patients with metastatic or locally advanced esophageal or EGJ carcinoma (SCC and adenocarcinoma) with an epicenter 1 to 5 cm above the EGJ and who are not eligible for resection or chemoradiation, regardless of PD-L1 expression [<a href="#rid48">48</a>]. However, the benefit of adding immunotherapy to chemotherapy for tumors with low PD-L1 expression, especially adenocarcinomas, is controversial. Notably, the EMA has restricted approval of pembrolizumab to esophageal cancers with CPS ≥10 [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1">The benefit of immunotherapy for adenocarcinomas with low PD-L1 expression is discussed above (See <a class="local">'Low or absent PD-L1 expression'</a> above.) </p><p></p><p class="bulletIndent1">The benefit of immunotherapy for SCCs with low expression of PD-L1 is addressed in detail below. (See <a class="local">'Low PD-L1 expression (squamous cell carcinoma)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Camrelizumab, sintilimab, tislelizumab, and </strong><a class="drug drug_general" data-topicid="143227" href="/d/drug information/143227.html" rel="external">toripalimab</a> – Randomized trials have shown a comparable survival benefit for the addition of camrelizumab, sintilimab, tislelizumab, or toripalimab to chemotherapy (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus a fluoropyrimidine or <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>) compared with chemotherapy alone in patients with previously treated advanced esophageal SCC [<a href="#rid58">58-61</a>].</p><p></p><p class="headingAnchor" id="H2750298724"><span class="h4">Low PD-L1 expression (squamous cell carcinoma)</span><span class="headingEndMark"> — </span>As noted above, largely based on the first analysis of KEYNOTE-590, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, in combination with platinum- and fluoropyrimidine-based chemotherapy, for the treatment of patients with metastatic or locally advanced esophageal or EGJ carcinoma (both SCC and adenocarcinoma) who are ineligible for resection or chemoradiation, and without regard for level of PD-L1 expression. However, data are mixed for the benefit of immunotherapy in patients with SCC and low PD-L1 expression. </p><p>Data for chemoimmunotherapy in patients with esophageal/gastric adenocarcinoma with low or absent PD-L1 expression is discussed above. (See <a class="local">'Low or absent PD-L1 expression'</a> above.)</p><p>Data from clinical trials are mixed on the benefits of upfront immunotherapy in those with SCC and low PD-L1 expression. </p><p class="bulletIndent1"><span class="glyph">●</span>Several international trials (ie, not restricted to Asia) in patients with esophageal adenocarcinoma showed no overall survival benefit for the addition of immunotherapy to chemotherapy among those with low PD-L1 expression (ie, TPS &lt;1 percent [CheckMate 648] or CPS &lt;10 [KEYNOTE-590]) [<a href="#rid35">35,47,62</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in another international clinical trial (RATIONALE-306) that used an alternative PD-L1 scoring system which resembles CPS (PD-L1 tumor area positivity [TAP]), the addition of immunotherapy (tislelizumab) to chemotherapy demonstrated a non-statistically significant trend towards improved OS among those with PD-L1 TAP &lt;10 [<a href="#rid61">61</a>]. </p><p></p><p>Several meta-analyses of randomized clinical trials suggest some benefit for immunotherapy in SCC with low PD-L1 expression. Data are as follows: </p><p class="bulletIndent2"><span class="glyph">•</span>One analysis of 17 randomized trials conducted in either the first- or second-line setting in either adenocarcinoma or SCC evaluated the OS benefit of immunotherapy for high versus absent/low PD-L1 expression [<a href="#rid63">63</a>]. Among patients with SC, PD-L1 expression was the strongest predictor of benefit from immunotherapy (HR 0.60, 95% CI 0.53-0.68 for high TPS, and HR 0.84, 95% CI 0.75-0.95 for low TPS). Of the seven trials restricted to SCC, five trials enrolled Asian patients only. In addition, patients with SCC appeared to benefit more from immune checkpoint inhibitors than those with adenocarcinoma (HR 0.71, 95% CI, 0.67-0.77 for OS in SCC; HR 0.87, 95% CI, 0.80-0.96 for OS in adenocarcinoma). PD-L1 expression [ie, CPS ≥10 and TPS ≥1 percent]) also appeared to be more common in SCC than adenocarcinoma [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of five randomized trials [<a href="#rid35">35,47,58-60</a>] analyzed the benefit of adding immunotherapy to chemotherapy in patients with SCC stratified by PD-L1 expression (high versus low) using two expression scoring criteria (TPS ≥1/&lt;1 percent, and CPS ≥10/&lt;10) [<a href="#rid64">64</a>]. An OS benefit for chemoimmunotherapy relative to chemotherapy alone was seen in those with TPS &lt;1 percent (HR 0.77, 95% CI 0.56-0.97) and CPS &lt;10 percent (HR 0.77, 95% CI 0.66-0.89).</p><p></p><p class="headingAnchor" id="H3752989175"><span class="h3">Deficient mismatch repair</span><span class="headingEndMark"> — </span>We suggest first-line immunotherapy rather than chemotherapy alone for individuals with dMMR/MSI-H esophagogastric adenocarcinomas regardless of PD-L1 expression. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> monotherapy and immunotherapy plus systemic chemotherapy are both acceptable options in this setting. (See  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Defective mismatch repair'</a>.)</p><p>Refractory cancers with dMMR/MSI-H may be susceptible to inhibition of the PD-1/PD-L1 pathway, as demonstrated in the KEYNOTE-158 study, which was conducted in patients with previously treated disease at a variety of primary sites, including the esophagus and stomach. In May 2017, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for treatment of a variety of advanced solid tumors, including gastric cancers, that had MSI-H or dMMR, that had progressed following prior treatment, and for which there were no satisfactory alternative treatment options, the first such approval of a tissue-agnostic anticancer treatment. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p>The following data provide support for front-line <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy or a combined approach of immunotherapy plus chemotherapy compared with chemotherapy alone for previously untreated patients with dMMR esophagogastric cancer, most of whom also express PD-L1:</p><p class="bulletIndent1"><span class="glyph">●</span>An exploratory analysis of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for treatment of dMMR/MSI-H esophagogastric cancer included a subset of 50 patients enrolled on the KEYNOTE-062 trial whose tumors had high levels of MSI plus PD-L1 expression as well as 34 other patients treated with pembrolizumab for a later line of systemic therapy in KEYNOTE-059 and KEYNOTE-060 [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Defective mismatch repair'</a>.)</p><p></p><p class="bulletIndent1">As noted above, in the entire cohort, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> significantly improved OS relative to chemotherapy alone for those with CPS ≥10, and was less toxic, although objective response rates were lower. Overall survival with pembrolizumab plus chemotherapy was not superior in those with CPS ≥1, or in those with a CPS ≥10 although combined therapy was associated with a higher objective response rate [<a href="#rid45">45</a>]. (See <a class="local">'HER2-negative adenocarcinoma'</a> above.)</p><p></p><p class="bulletIndent1">In a later analysis restricted to the 50 patients with dMMR/MSI-H tumors in addition to CPS ≥1, compared with chemotherapy alone, combined therapy did provide a modest but significant benefit in overall survival (median not reached versus 8.5 months; 12 month survival 71 versus 47 percent, 24 month survival 65 versus 26 percent) and PFS (median not reached versus 6.6 months), and a twofold higher objective response rate (65 versus 37 percent) [<a href="#rid65">65</a>]. Furthermore, compared with chemotherapy alone, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy was also associated with a higher objective response rate (57 versus 37 percent), longer duration of response (21.2 versus 7 months), higher PFS (median 11.2 versus 6.6 months), and longer overall survival (median not reached versus 8.5 months, 12-month survival 79 versus 47 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced benefit for combined therapy among those with dMMR/MSI-H tumors was also suggested in a subset analysis of the CheckMate 649 trial [<a href="#rid41">41</a>]. Among the 44 patients with dMMR/MSI-H tumors who were randomized to <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus chemotherapy, median survival was 38.7 versus 12.3 months with chemotherapy alone (HR for death 0.38, 95% CI 0.17-0.84); the benefits were even greater in the 34 patients with both CPS ≥5 and dMMR (median 44.8 versus 8.8 months, HR 0.32). (See <a class="local">'High PD-L1 expression'</a> above.)</p><p></p><p class="headingAnchor" id="H2569987813"><span class="h3">Selection of the chemotherapy backbone for combined therapy</span><span class="headingEndMark"> — </span>When immunotherapy is combined with cytotoxic therapy in the first-line setting, the optimal cytotoxic chemotherapy backbone is not established. The CheckMate 649 and ATTRACTION-4 trials used an oxaliplatin-based regimen with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, while the KEYNOTE-590 and KEYNOTE-062 trials used <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and FU in conjunction with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. Regardless of the specific immune checkpoint inhibitor, we generally prefer an oxaliplatin-containing regimen for most patients. (See <a class="local">'Oxaliplatin combinations'</a> below.)</p><p>Where camrelizumab is available (mainly China), a chemotherapy doublet of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, as was used in the ESCORT-1<sup>st</sup> trial, is an appropriate option. (See <a class="local">'Squamous cell cancers'</a> above.)</p><p class="headingAnchor" id="H1036697631"><span class="h2">HER2-overexpressing adenocarcinomas</span><span class="headingEndMark"> — </span>Patients with unresectable, locally advanced, recurrent, or metastatic gastric or esophageal adenocarcinoma who are potential candidates for <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> should have their tumors assayed for the presence of human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification using specific criteria developed for esophagogastric adenocarcinomas. We suggest the addition of trastuzumab to chemotherapy in patients with HER2-positive tumors (as defined by 3+ immunohistochemistry [IHC] staining or fluorescence in situ hybridization [FISH] positivity), as long as they do not have a contraindication to trastuzumab. We also suggest the addition of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to trastuzumab, based on an interim analysis of the phase III KEYNOTE-811 trial.</p><p>Between 7 and 38 percent of gastroesophageal adenocarcinomas have amplification and/or overexpression of HER2 [<a href="#rid66">66-75</a>]. The frequency of overexpression is slightly greater for cancers of the EGJ as compared with those of the stomach (32 versus 21 percent) [<a href="#rid66">66-68,76-82</a>]. Overexpression in the stomach varies according to histologic type (intestinal-type more than diffuse-type gastric cancers; 3 to 23 versus 0 to 6 percent, respectively [<a href="#rid80">80</a>]) and with differentiation (well and moderately differentiated more than poorly differentiated). (See <a class="local">'Assessment of HER2 status and selection of candidates for trastuzumab'</a> below.)</p><p>High levels of HER2 overexpression and/or amplification identify those patients who might potentially benefit from treatment with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, a humanized monoclonal antibody that targets the extracellular domain of the HER2 receptor, inhibits downstream signal activation, and induces antibody-dependent cellular toxicity.</p><p class="headingAnchor" id="H500629547"><span class="h3">Benefit of trastuzumab</span><span class="headingEndMark"> — </span>The benefit of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> in advanced HER2-positive adenocarcinoma of the stomach or EGJ was addressed in the phase III ToGA trial, which compared standard chemotherapy (six courses of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus either infusional FU or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>) with and without trastuzumab (8 mg/kg loading dose, then 6 mg/kg every three weeks until disease progression) [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer", section on 'Trastuzumab-containing regimens for HER2-positive advanced adenocarcinomas'</a>.)</p><p>All tumors were screened for HER2 status by both IHC and FISH, and patients were eligible for the trial if their tumor was IHC positive (IHC 3+) or FISH positive (ie, showing a HER2/chromosome enumeration probe 17 [CEP17] ratio of 2 or greater) [<a href="#rid83">83,84</a>]. Among enrolled patients (n = 594 of the 3807 screened), almost all tumors were FISH positive, whereas protein expression by IHC varied (47 percent 3+, 30 percent 2+, and 22 percent 0 or 1+).</p><p>The objective response rate was significantly higher with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> (47 versus 35 percent). At a median follow-up of 17 to 19 months, median overall survival (the primary endpoint) was modestly but significantly better with trastuzumab (13.8 versus 11.1 months, HR 0.74, 95% CI 0.60-0.91). The toxicities in the two arms were comparable, except that a higher number of trastuzumab-treated patients had grade 3 or 4 diarrhea (9 versus 4 percent) and an asymptomatic decrease in left ventricular ejection fraction (5 versus 1 percent). Only one patient developed grade 3 to 4 heart failure (versus two in the control group). Exploratory analysis in subgroups defined by protein expression suggested that trastuzumab was most effective in prolonging survival in the subgroup of patients with IHC 3+ tumors (HR for death 0.66, 95% CI 0.50-0.87), was less effective in patients with IHC 2+ tumors (HR 0.78, 95% CI 0.55-1.10), and was ineffective in those with HER2 gene-amplified (ie, FISH-positive) but non-protein-expressing (IHC 0 or 1+) tumors.</p><p>Based on these data, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> was approved, in combination with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and a fluoropyrimidine, for the treatment of patients with metastatic HER2-overexpressing gastric or EGJ adenocarcinomas who have not received prior treatment for metastatic disease. Patients with advanced gastric cancer who are potential candidates for trastuzumab should be screened to determine HER2 status.</p><p>Higher-dose <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> maintenance dosing (10 mg/kg every three weeks, as compared with the doses of 6 mg/kg every three weeks that were used in the ToGA trial) was not associated with greater efficacy in the phase III HELOISE trial [<a href="#rid85">85</a>], and this approach cannot be recommended. Furthermore, the addition of <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a>, a humanized HER2-targeted monoclonal antibody that binds to a different epitope on the HER2 receptor protein than trastuzumab, was not beneficial in the phase III JACOB trial [<a href="#rid86">86</a>], and this approach cannot be recommended.</p><p class="headingAnchor" id="H2061058583"><span class="h4">Specific chemotherapy backbone</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> was studied with fluoropyrimidine/<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> regimens in the randomized ToGA trial, many clinicians incorporate trastuzumab into their first-line regimen of choice (including cisplatin-free regimens, such as FOLFOX and XELOX/CAPOX, or weekly <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>), despite the lack of phase III trials to demonstrate benefit of trastuzumab in these settings. Consensus-based guidelines from the National Comprehensive Cancer Network also support this approach, recommending the addition of trastuzumab to any chemotherapy combination for patients with HER2-overexperssing tumors [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer", section on 'Trastuzumab-containing regimens for HER2-positive advanced adenocarcinomas'</a>.)</p><p>At least some data suggest potential superiority for a doublet regimen containing <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> over a fluoropyrimidine/<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> regimen when combined with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>. A meta-analysis compared cytotoxic backbones for first-line trastuzumab-containing regimens in 15 published studies (557 patients, a mix of prospective and retrospective cohort studies); HRs and CIs were calculated by extraction of the published Kaplan-Meier survival curves [<a href="#rid88">88</a>]. The following conclusions were made compared with the ToGA trial regimen (trastuzumab, cisplatin, and a fluoropyrimidine):</p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival was significantly longer with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus a doublet regimen of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and either <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or FU (median 20.7 versus 16 months, HR 0.75, 95% CI 0.59-0.99), and it was also less toxic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> plus a doublet of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and S-1 showed no overall survival difference, but there was a different toxicity profile, including less hand-foot syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> as a singlet backbone showed worse survival and more toxicity compared with the ToGA trial regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> with a triplet cytotoxic backbone (eg, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, a platinum, and a fluoropyrimidine) or with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus a doublet backbone showed no survival benefit and a worse toxicity profile.</p><p></p><p>As noted above, emerging data suggest high response rates with first-line oxaliplatin- and irinotecan-containing regimens, such as <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, and FU (FOLFIRINOX), albeit with greater toxicity than would be expected with an oxaliplatin-containing doublet. As an example, a phase II open label study administered the FOLFIRINOX regimen  (<a class="graphic graphic_table graphicRef79571" href="/d/graphic/79571.html" rel="external">table 5</a>) to 67 patients with previously untreated metastatic gastroesophageal cancer; the 26 who had HER2-positive disease received concurrent <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> as a 6 mg/kg initial loading dose, followed by 4 mg/kg every 14 days [<a href="#rid89">89</a>]. (See <a class="local">'FOLFIRINOX'</a> below.)</p><p>The objective response rate in the HER2-positive cohort was 85 percent, with one complete clinical response; median PFS and overall survival durations were 13.8 and 19.6 months, respectively. The most common severe toxic effects were neutropenia (89 percent, 65 percent grade ≥3), diarrhea (58 percent; 19 percent grade ≥3), peripheral sensory neuropathy (46 percent), nausea (35 percent, 8 percent grade ≥3), and fatigue (35 percent).</p><p>In our view, for most patients, a doublet backbone of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus a fluoropyrimidine is preferable to <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus a fluoropyrimidine when used with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> for HER2-positive esophagogastric cancer; where available, S-1 can substitute for <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or FU when specific toxicities are encountered. Given the absence of randomized data, we do not favor FOLFIRINOX as a front-line regimen, either in HER2-positive or HER2-negative disease.</p><p>Patients who are receiving a capecitabine-containing regimen should probably not take proton pump inhibitors concurrently. Concerns have been raised that higher gastric pH levels may inhibit dissolution and absorption of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, adversely impacting efficacy [<a href="#rid90">90,91</a>].</p><p class="headingAnchor" id="H1025436353"><span class="h4">Adding pembrolizumab</span><span class="headingEndMark"> — </span>The safety and efficacy of combining the immune checkpoint inhibitor <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> with first-line <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus platinum-containing chemotherapy was first shown in a single-arm open-label phase II trial of 37 previously untreated patients with HER2-positive esophageal, gastric, or EGJ cancer [<a href="#rid92">92</a>]. At a median follow-up of 13 months, 26 of the 37 patients (70 percent) were progression free at six months (the primary endpoint). The most common grade 3 or 4 adverse events were lymphocytopenia (19 percent) and hypokalemia, hypomagnesemia, or hyponatremia (16 percent). Serious adverse events occurred in only two patients (grade 3 nephritis leading to treatment discontinuation). A similar level of efficacy and manageable safety was subsequently shown in a second phase Ib/II trial [<a href="#rid93">93</a>].</p><p>Benefit was confirmed in the multicenter phase III KEYNOTE-811 trial, in which 692 patients with HER2-positive advanced gastric or EGJ adenocarcinoma who had not received systemic therapy for advanced disease and no autoimmune disease requiring systemic therapy within two years or medical condition requiring immunosuppression were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or placebo given with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus three-week cycles of platinum-containing cytotoxic chemotherapy (investigator’s choice of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> 80 mg/m<sup>2</sup> on day 1 for up to six cycles plus FU 800 mg/m<sup>2</sup> per day for five days each cycle, or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> 1000 mg/m<sup>2</sup> per day for 14 days plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> 130 mg/m<sup>2</sup> on day 1 up to six to eight cycles [CAPOX]). Pembrolizumab/placebo and trastuzumab were both administered on day 1 of each cycle, in a manner identical to that used in the phase II trial described above.</p><p>A preplanned interim analysis was performed after the first 264 patients were enrolled; 87 percent had received CAPOX, and 87 percent had tumors that overexpressed PD-L1 (CPS ≥1, although this was not a requirement for enrollment) [<a href="#rid94">94</a>]. The objective response rate was significantly higher with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (74 percent [95% CI 66-82] versus 52 percent [95% CI 43-61]), and there were more complete responders (11 versus 3 percent). The median duration of response was 10.6 months (range 1.1<sup>+</sup> to 16.5<sup>+</sup>) with pembrolizumab versus 9.5 months (range 1.4<sup>+</sup> to 15.4<sup>+</sup>), but more patients in the pembrolizumab group had an ongoing response at ≥6 months (70 versus 61 percent).</p><p>Largely based on this interim analysis, the US FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, in combination with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> and fluoropyrimidine plus platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic esophageal or EGJ (tumors with epicenter 1 to 5 centimeters above the EGJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation [<a href="#rid95">95</a>]. Options include pembrolizumab plus FOLFOX and trastuzumab,  (<a class="graphic graphic_table graphicRef141603" href="/d/graphic/141603.html" rel="external">table 6</a>) and pembrolizumab plus CAPOX and trastuzumab  (<a class="graphic graphic_table graphicRef141602" href="/d/graphic/141602.html" rel="external">table 7</a>). </p><p class="headingAnchor" id="H115954075"><span class="h4">Assessment of HER2 status and selection of candidates for trastuzumab</span><span class="headingEndMark"> — </span>In comparison with breast carcinomas, the heterogeneity of immunostaining for biomarkers such as human epidermal growth factor receptor 2 (HER2) is greater in gastroesophageal adenocarcinoma tumors and the possibility of false-negative testing is higher [<a href="#rid80">80,96</a>]. Because of this intratumoral heterogeneity, which is present even before metastatic spread has occurred [<a href="#rid97">97</a>], analyzing HER2 positivity in fewer than six biopsy samples leads to a false-negative rate that may be as high as 9 percent [<a href="#rid98">98-103</a>]. Furthermore, HER2 protein expression in gastroesophageal adenocarcinomas tends to spare the digestive luminal membrane, resulting in membrane staining that is not completely circumferential in contrast with breast cancers [<a href="#rid79">79,83,84</a>]. These differences underscore the importance of utilizing tumor-specific criteria to assess HER2 expression in clinical practice. (See  <a class="medical medical_review" href="/d/html/119517.html" rel="external">"Gastric cancer: Pathology and molecular pathogenesis", section on 'HER2 overexpression'</a>.)</p><p>Given the differences in interpretive criteria for determining HER2 status in gastroesophageal as compared with breast cancers [<a href="#rid66">66,83,84,104</a>], an expert panel convened by the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology undertook a systematic review of the published literature to provide an evidence-based joint guideline on HER2 testing and clinical decision-making in gastroesophageal adenocarcinomas [<a href="#rid80">80</a>]. The panel's recommendations were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients who have documented advanced gastroesophageal adenocarcinoma and who are considered good candidates for combination therapy that includes <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> should have their tumor tissue tested for HER2 overexpression and/or amplification prior to trastuzumab treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For biopsy or resection specimens, a minimum of five specimens (optimally six to eight) should be tested to account for intratumoral heterogeneity when possible. If there is documentation of HER2 positivity on any specimen, the treating clinician does not need to request additional HER2 testing on additional specimens.</p><p></p><p class="bulletIndent1">HER2 testing on fine needle aspirate specimens is an acceptable alternative [<a href="#rid83">83,105</a>]. However, specimens obtained in cytology specimens may not be truly representative given the limited sampling of the tumor. If there is concern about specimen adequacy and HER2 testing is negative, additional available primary or metastatic tumor tissue should be tested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When HER2 status is being evaluated, laboratories/pathologists should perform/order IHC staining first. Pathologists should use the Ruschoff/Hoffmann method when scoring IHC results  (<a class="graphic graphic_table graphicRef110996" href="/d/graphic/110996.html" rel="external">table 8</a>) and should select the tissue block with the areas of lowest grade or intestinal morphology for testing. A positive result is IHC 3+. A negative result is IHC 0 to 1+ [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FISH or another in situ hybridization (ISH) method is recommended only when the IHC result is 2+ (equivocal) to determine amplification status. In many studies, ISH-positive results are observed in 30 to 50 percent of IHC 2+ tumors [<a href="#rid81">81,106-109</a>]. A variety of in situ visualization techniques to evaluate HER2 amplification, including FISH and brightfield ISH using either a HER2 probe or dual HER2 and centromere (CEP17) probes, are all acceptable strategies. A ratio of HER2 signal to CEP17 signal ≥2 is considered positive, while a HER2/CEP17 ratio &lt;2 is considered negative. An algorithmic approach to assessing HER2 status on surgical and biopsy material is presented in the figure  (<a class="graphic graphic_algorithm graphicRef110995" href="/d/graphic/110995.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HER2-positive tumors (IHC 3+ or ISH positive), clinicians should offer combination chemotherapy and HER2-targeted therapy as the initial treatment for appropriate patients. The addition of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> can increase the response rate and prolong PFS and overall survival. Clinicians should not offer HER2-targeted therapy until HER2 positivity is confirmed; for symptomatic patients, it is recommended to begin combination cytotoxic chemotherapy as soon as possible while awaiting confirmation of HER2 status.</p><p></p><p>However, even when these guidelines are followed, there can be significant discrepancies in local HER2 assessment, particularly in tumor specimens with intermediate levels of HER2 expression. These discrepancies can be illustrated by the prospective multicenter VARIANZ study, which was designed to determine factors predicting <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> response or resistance in HER2+ metastatic gastric cancer [<a href="#rid110">110</a>]. In the 374 patients for whom HER2 status was determined both locally and centrally, there was a high deviation rate (23 percent) between centrally confirmed and locally interpreted HER2 test results, with most (74 of 77 cases) reflecting an inability to confirm locally assessed HER2 positivity by central testing. Tumors were classified as IHC+ centrally if at least 10 percent of tumor cells stained positive in resection specimens, and if at least five adjacent tumor cells stained positive in biopsies (IHC score 3+ and 2+ if findings confirmed by in situ hybridization). The 60 patients who received trastuzumab and had a centrally confirmed HER2+ test had a significantly longer survival than did the 65 patients who received trastuzumab for a centrally unconfirmed locally assessed HER2+ tumor (median 20.5 versus 10.9 months).</p><p>In an attempt to devise alternative criteria for selection of patients for HER2-directed treatment, the percentage of IHC-positive tumor cells as a fraction of all tumor cells present in the local and central specimens was calculated, and quantitative reverse transcriptase polymerase chain reaction was applied to quantify HER2 mRNA. In this analysis, significantly more tumor cells stained positive for HER2 in the centrally confirmed versus nonconfirmed cases (59 versus 13 percent), and the HER2 amplification signal ratio (HER2:CEP17) was significantly higher as well (7.2 versus 1.5). The authors concluded that a minimum of 40 percent IHC HER2+ tumor cells and a HER2:CEP17 amplification ratio of ≥3 were optimal thresholds for predicting benefit from <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>.</p><p class="headingAnchor" id="H3775731756"><span class="h5">Contraindications</span><span class="headingEndMark"> — </span>While there are no published guidelines for exclusion of patients for <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> on the basis of excess cardiac risk, many clinicians caring for patients with breast cancer use the cardiac ineligibility criteria from the North American adjuvant trastuzumab trials  (<a class="graphic graphic_table graphicRef74571" href="/d/graphic/74571.html" rel="external">table 9</a>). It seems reasonable to adopt this approach in esophagogastric cancer as well.</p><p class="headingAnchor" id="H4146523043"><span class="h3">Lapatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">Lapatinib</a> is an orally active small-molecule inhibitor of both epidermal growth factor receptor (EGFR) and HER2; benefit for the addition of lapatinib to weekly <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> versus paclitaxel alone could not be demonstrated in patients with previously treated, advanced gastric cancer on the TyTAN trial. (See  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-positive adenocarcinoma'</a>.)</p><p>Benefit from the addition of <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a> to first-line chemotherapy was also not shown in the TRIO-013/LOGiC trial of XELOX/CAPOX with or without lapatinib for first-line treatment in 545 patients with advanced gastroesophageal cancer. The primary endpoint (overall survival of the patients who were centrally confirmed to be FISH positive for HER2) was not significantly better with lapatinib (median survival 12.2 versus 10.5 months, HR 0.91, 95% CI 0.73-1.12) [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H662041107"><span class="h3">Implications of HER2 expression for prognosis</span><span class="headingEndMark"> — </span>In contrast to breast cancer (where human epidermal growth factor receptor 2 [HER2] expression is an adverse prognostic factor), the association between HER2 expression/amplification and prognosis in esophagogastric cancer is uncertain. (See  <a class="medical medical_review" href="/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'HER2 status and predicting treatment response'</a>.)</p><p>The following data are available:</p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective evaluations of HER2 expression and gene amplification in relation to prognosis for gastric/gastroesophageal junction adenocarcinomas have been performed in at least seven studies of prospectively enrolled clinical trial cohorts  (<a class="graphic graphic_table graphicRef89512" href="/d/graphic/89512.html" rel="external">table 10</a>) [<a href="#rid106">106,112-117</a>]. These studies adopted the HER2 interpretive criteria used in ToGA, and patients <strong>did not</strong> receive HER2-targeted therapy. The results are conflicting. Four studies found that HER2 was not associated with prognosis [<a href="#rid113">113-115,117</a>], while one reported a significant positive association [<a href="#rid112">112,118</a>], and one other reported a trend toward improved survival with HER2 overexpression [<a href="#rid116">116</a>]. In one study, HER2 overexpression was associated with shorter survival, but only among patients who received adjuvant postoperative chemoradiotherapy after potentially curative resection [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While the prognostic impact of HER2 overexpression was not formally evaluated in the ToGA study, the median overall survival of patients in the control arm appeared to increase as HER2 protein expression levels increased (median survival durations were 7.2, 10.2, 10.8, and 12.3 months for those with IHC 0/FISH-positive, IHC 1+/FISH-positive, IHC 2+/FISH-positive, and IHC 3+/FISH-positive tumors, respectively) [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in a meta-analysis of 49 gastric cancer studies (n = 11,337, from 1990 to 2011, stage I to IV), patients with (versus without) HER2 overexpression had shorter five-year overall survival (42 versus 52 percent) [<a href="#rid119">119</a>]. However, the generalizability of this meta-analysis (which did not include the seven studies or the ToGA trial results described above) may be limited because only one study was performed after disease-specific HER2 interpretive criteria were established through ToGA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with esophageal adenocarcinomas, the prognostic impact of HER2 has not been as extensively examined as it has been in gastric cancer (sample sizes typically &lt;200 cases), but the data are likewise conflicting [<a href="#rid76">76-78,120-122</a>]. The largest study (n = 713), which used disease-specific HER2 interpretive criteria, found no association between HER2 overexpression and prognosis [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In modern series, the prognostic impact of HER2 overexpression is likely to be linked to the use of anti-HER2 therapy. In one analysis of 924 patients with advanced esophagogastric cancer receiving first-line chemotherapy, those with HER2-positive tumors receiving HER2-targeted therapy had a significantly higher survival as compared with those with HER2-negative tumors (HR for death 0.75, 95% CI 0.61-0.91) [<a href="#rid123">123</a>].</p><p></p><p class="headingAnchor" id="H1731259419"><span class="h2">Cytotoxic chemotherapy options</span><span class="headingEndMark"> — </span>For SCC and adenocarcinomas that do not overexpress HER2 and are not candidates for immunotherapy, the choice of the chemotherapy regimen is empiric. For most patients who are candidates for aggressive combination therapy, we suggest a platinum- and fluoropyrimidine-containing doublet combination regimen. Acceptable options include FOLFOX, or XELOX/CAPOX.</p><p>Where S-1 is available, S-1 in combination with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is also a reasonable choice for first-line therapy that does not require central venous access.</p><p>For older patients or those with a poor performance status or significant comorbidity, we suggest monotherapy rather than combination chemotherapy. Options include leucovorin-modulated FU alone, single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, single-agent <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, or low-dose weekly taxanes.</p><p class="headingAnchor" id="H5"><span class="h3">Single-agent chemotherapy</span><span class="headingEndMark"> — </span>In general, combination chemotherapy regimens provide higher response rates than do single agents, but this translates into only modestly longer durations of disease control and survival, which are measured in weeks to a few months. Single-agent chemotherapy is an appropriate option for patients who are not candidates for aggressive combination chemotherapy. Another option for frail or older adult individuals is reduced-dose XELOX/CAPOX. (See <a class="local">'Chemotherapy dosing in older and frail patients'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Taxanes and </strong><strong>irinotecan</strong> – In general, response rates with taxane or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> monotherapy are slightly higher than those seen with older agents, such as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, but toxicity is prominent in many cases, and median survival durations have not been consistently greater than nine months with any agent. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In multiple studies, monotherapy with either single-agent <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> produced response rates in the range of 15 to 24 percent [<a href="#rid8">8-10,124-128</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two reports involving 83 previously untreated patients, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> was associated with response rates of 14 and 20 percent, respectively [<a href="#rid129">129,130</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoropyrimidines</strong> – Efficacy is modest for leucovorin-modulated FU [<a href="#rid131">131-133</a>].</p><p></p><p class="bulletIndent1">Several orally active fluoropyrimidines are available, which, as single agents, are associated with response rates as high as 41 percent, but median survival durations have not exceeded nine months in any report [<a href="#rid134">134-141</a>]. Phase III studies have demonstrated equivalence between infusional FU, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, and S-1.</p><p></p><p class="bulletIndent1">Patients who are receiving a capecitabine-containing regimen should probably not take proton pump inhibitors concurrently. Concerns have been raised that higher gastric pH levels may inhibit dissolution and absorption of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, adversely impacting efficacy [<a href="#rid90">90,91</a>].</p><p></p><p class="bulletIndent1">S-1 is an oral formulation of the following components in a 1:0.4:1 ratio [<a href="#rid136">136</a>]: ftorafur (tegafur), the prodrug for cytotoxic FU; gimeracil (5-chloro-2,4-dihydroxypyridine), an inhibitor of dihydropyrimidine dehydrogenase (DPD), which prevents its degradation in the gastrointestinal tract, thus prolonging its half-life [<a href="#rid137">137</a>]; and oteracil (potassium oxonate), a specific inhibitor of one of the enzymes (orotate phosphoribosyl transferase) that phosphorylates FU in the intestine. Phosphorylated FU is thought to be mainly responsible for treatment-related diarrhea.</p><p></p><p class="bulletIndent1">The efficacy of S-1 alone (40 mg/m<sup>2 </sup>orally twice a day on days 1 to 28 every six weeks) was shown in the phase III JCOG 9912 trial, which was powered to demonstrate noninferiority of S-1 alone and superiority of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> over infusional FU monotherapy in 704 patients with unresectable or recurrent, previously untreated gastric adenocarcinoma [<a href="#rid138">138</a>].In the primary endpoint, PFS, S-1 was not inferior to infusional FU, and there were trends suggesting superiority over infusional FU (median PFS 4.2 versus 2.9 months). The response rate was higher with S-1 than with FU (28 versus 9 percent), and median overall survival was 11.4 versus 12.3 months. S-1 was associated with more grade 3 or 4 diarrhea than FU (8 versus &lt;1 percent). Otherwise, the side effect profile was comparable.</p><p></p><p class="bulletIndent1">S-1 monotherapy (40 to 60 mg twice daily on days 1 to 28 every six weeks) was directly compared with single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (1250 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days) in a Korean randomized phase II trial involving 91 older patients with previously untreated, advanced gastric cancer [<a href="#rid139">139</a>]. The two regimens were comparable with respect to overall response rate (29 versus 20 percent for S-1 and capecitabine, respectively), median time to tumor progression (4.2 versus 4.7 months), overall survival (median 8.2 versus 9.5 months), and treatment-related toxicity, with the exception of hand-foot syndrome (0 versus 7 percent).</p><p></p><p class="bulletIndent1">Thus, S-1 monotherapy appears active and well tolerated in cisplatin- and paclitaxel-refractory disease [<a href="#rid140">140</a>], and where available (not yet in the United States), it is a reasonable option in this setting; however, efficacy is more modest in patients with a poor performance status [<a href="#rid141">141</a>]. At least in Asian populations, S-1 monotherapy appears to be inferior to combination chemotherapy containing S-1 in previously untreated patients with advanced esophagogastric cancer [<a href="#rid142">142,143</a>]. (See <a class="local">'Cisplatin plus a fluoropyrimidine'</a> below.)</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Combination chemotherapy</span><span class="headingEndMark"> — </span>Higher response rates (up to 65 percent) are reported in phase II trials evaluating combination therapy in patients with advanced esophageal and gastric cancer. However, almost without exception, response rates have been lower in the setting of randomized trials. Furthermore, whether the higher response rates seen with combination as compared with single-agent chemotherapy translate into longer response duration or survival remains uncertain. In general, the higher response rates seen with combination regimens has translated into only modestly longer durations of disease control and survival, which are measured in weeks to a few months [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H2702511155"><span class="h4">Oxaliplatin combinations</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> combinations have been most extensively studied for metastatic colorectal cancer, they are also active in the treatment of esophagogastric cancer. A variety of different regimens have been studied in phase II trials (FOLFOX; <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, oxaliplatin, and infusional FU [EOF]; XELOX/CAPOX; S-1 plus oxaliplatin; <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus oxaliplatin with or without FU or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>), all of which are associated with response rates in the range of 40 to 67 percent and median survival durations between 8 and 15 months [<a href="#rid144">144-158</a>]. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer"</a>.)</p><p>Regimens containing <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and a taxane are discussed below. (See <a class="local">'Docetaxel-containing'</a> below.)</p><p>At least five phase III trials have directly compared oxaliplatin-based regimens with cisplatin-containing regimens (including <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and infusional FU [ECF]), all of which suggest at least comparable efficacy when <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> is substituted for cisplatin in combination regimens for patients with advanced esophagogastric cancer [<a href="#rid144">144,159-162</a>]. A meta-analysis of the REAL-2 trial [<a href="#rid159">159</a>] plus two other randomized phase II trials [<a href="#rid144">144,163</a>] that compared oxaliplatin-based regimens with cisplatin-based regimens showed that oxaliplatin was associated with significant improvements in PFS (HR 0.88, 95% CI 0.80-0.98) and overall survival (HR for death 0.88, 95% CI 0.78-0.99), and with less neutropenia, anemia, alopecia, and thromboembolic events, but with more neurotoxicity and diarrhea [<a href="#rid164">164</a>].</p><p>Benefit for the FOLFOX regimen is also supported by the results of CALGB 80403, a randomized phase II trial comparing ECF with FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>), both in combination with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, which concluded that response rates, PFS, and median overall survival were similar with either regimen [<a href="#rid157">157,158</a>].</p><p class="headingAnchor" id="H1586646815"><span class="h5">FOLFIRINOX</span><span class="headingEndMark"> — </span>We do not suggest <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, and FU (FOLFIRINOX) as a preferred option for first-line therapy, either in the setting of HER2-negative or HER2-positive disease.</p><p>Emerging data suggest high response rates with first-line <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and irinotecan-containing regimens such as FOLFIRINOX, albeit with greater toxicity than is typically seen for regimens containing either oxaliplatin or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. As an example, a phase II open-label study administered the FOLFIRINOX regimen  (<a class="graphic graphic_table graphicRef79571" href="/d/graphic/79571.html" rel="external">table 5</a>) to 67 patients with previously untreated metastatic gastroesophageal cancer; the 26 who had HER2-positive disease received concurrent <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> [<a href="#rid89">89</a>]. The objective response rate in those with HER2-negative disease was 61 percent, median PFS was 8.4 months, and median overall survival was 15.5 months. The most common severe toxic effects were neutropenia (91 percent, 79 percent grade ≥3), diarrhea (63 percent, 13 percent grade ≥3), peripheral sensory neuropathy (61 percent, 3 percent grade ≥3), nausea (48 percent, 6 percent grade ≥3), and fatigue (45 percent, 6 percent grade ≥3). The data for patients with HER2-positive disease are addressed below. (See <a class="local">'Specific chemotherapy backbone'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h4">Cisplatin plus a fluoropyrimidine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong><strong> plus FU</strong> – The combination of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus FU has been one of the most commonly used regimens in both metastatic and localized esophageal cancer due to its activity and well-established toxicity profile. In a randomized phase II study, 88 patients with locally advanced or metastatic esophageal SCC were assigned to either single-agent cisplatin (100 mg/m<sup>2</sup> every 21 days) or the same dose of cisplatin combined with FU (1000 mg/m<sup>2</sup> per day by continuous infusion on days 1 to 5) [<a href="#rid165">165</a>]. Although the response rate was higher for the doublet (35 versus 19 percent), the median survival (33 versus 28 weeks) and one-year survival rate (34 versus 27 percent) were not significantly different. Furthermore, there was a 17 percent treatment-related mortality rate (primarily due to sepsis and cerebrovascular episodes) in the cisplatin plus FU arm.</p><p></p><p class="bulletIndent1">A similar degree of activity (response rate 27 percent; median survival six months) was reported with much less toxicity (treatment-related mortality rate 3 percent) in a second study that used split-dose <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (20 mg/m<sup>2 </sup>per day on days 1 to 5) in combination with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> calcium and bolus FU (300 mg/m<sup>2</sup> per day for five days) [<a href="#rid166">166</a>].</p><p></p><p class="bulletIndent1">Combinations of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus FU and an anthracycline are discussed below. (See <a class="local">'Epirubicin, cisplatin, and fluorouracil'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong><strong> plus </strong><strong>capecitabine</strong> – <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> is a unique, rationally designed oral fluoropyrimidine that undergoes a three-step enzymatic activation process, the last of which occurs selectively within the tumor tissue itself. The drug passes intact through the bowel and reaches the liver, where it is converted first into deoxyfluorocytidine by a carboxylesterase and then into 5-deoxfluorouridine, which reaches the tumor, where it is transformed into its active form, FU, by thymidine phosphorylase.</p><p></p><p class="bulletIndent1">The comparable efficacy of regimens substituting <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for infusional FU was directly studied in two randomized trials [<a href="#rid159">159,167</a>].</p><p></p><p class="bulletIndent1">A meta-analysis of these two trials concluded that, compared with FU combinations, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> combinations were associated with higher response rates (odds ratio 1.38, 95% CI 1.10-1.73) and better overall survival (HR for death 0.87, 95% CI 0.77-0.98) [<a href="#rid168">168</a>].</p><p></p><p class="bulletIndent1">Although these data suggest that the efficacy of regimens that substitute <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for infusional FU is at least as good and that the use of capecitabine allows patients to avoid infusion pumps and a central venous catheter, the out-of-pocket cost of capecitabine is significantly higher than FU. This may be an important issue for patients whose health insurance coverage requires significant out-of-pocket expense for the capecitabine. Additionally, an oral chemotherapy agent requires both patient motivation and reliable upper gastrointestinal tract function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong><strong> plus S-1</strong> – S-1 is an oral fluoropyrimidine that includes ftorafur (tegafur), gimeracil (5-chloro-2,4-dihydroxypyridine, a potent inhibitor of DPD), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea). (See <a class="local">'Single-agent chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1">S-1 in combination with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is highly active in Asian patients [<a href="#rid142">142,169</a>]. A report from the SPIRITS trial supports a significant benefit for combined S-1 plus cisplatin over S-1 alone in terms of both response rate (54 versus 31 percent) and median survival (13 versus 11 months, p = 0.04) in an Asian population [<a href="#rid142">142</a>]. Rates of grade 3 or 4 neutropenia (40 versus 11 percent), anemia (26 versus 4 percent), nausea (11 versus 1 percent), and anorexia (30 versus 6 percent) were also significantly higher.</p><p></p><p class="bulletIndent1">A subsequent randomized phase II trial from Japan demonstrated comparable outcomes for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus S-1 compared with cisplatin plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for first-line treatment of advanced gastric cancer [<a href="#rid170">170</a>].</p><p></p><p class="bulletIndent1">Ftorafur is metabolized differently in Western and Asian populations on account of polymorphic differences in the cytochrome P450 2A6 (<em>CYP2A6</em>) gene; as a result, the maximally tolerated dose differs. Western experience with combined S-1 plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for advanced gastric cancer is limited but also promising [<a href="#rid171">171,172</a>]. As an example, in a multicenter phase II trial in which 72 patients received S-1 (25 mg/m<sup>2</sup> twice daily on days 1 through 21) plus cisplatin (75 mg/m<sup>2</sup> on day 1) every 28 days, the objective response rate was 55 percent, and the median duration of response was more than five months [<a href="#rid172">172</a>]. The safety profile was favorable; the most frequent grade 3 or 4 toxicities were fatigue/asthenia (24 percent), emesis (17 percent), nausea (15 percent), diarrhea (13 percent), and neutropenia (19 percent).</p><p></p><p class="bulletIndent1">The results from the phase II S-1 plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> trial led to the initiation of a global prospective randomized phase III trial, the FLAGS trial, which randomly assigned 1053 patients to cisplatin plus either FU or S-1. Median overall survival (the primary endpoint) was not significantly inferior with cisplatin plus S-1 as compared with cisplatin plus FU (8.6 versus 7.9 months) [<a href="#rid173">173</a>]. Furthermore, cisplatin plus S-1 had a more favorable side effect profile than cisplatin plus FU (grade 3 or 4 neutropenia in 19 versus 40 percent, stomatitis in 1 versus 14 percent, and hypokalemia in 4 versus 11 percent) and fewer treatment-related deaths (2.5 versus 4.9 percent) [<a href="#rid174">174</a>]. The lower cisplatin dose intensity in the cisplatin plus S-1 arm (75 versus 100 mg/m<sup>2</sup> on day 1 with cisplatin plus FU) may have contributed to the survival and toxicity results.</p><p></p><p class="bulletIndent1">This study was not seen as a success, as many expected superiority of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus S-1 over cisplatin plus FU based on the JCOG 9912 study (described above) [<a href="#rid138">138</a>]. Although a subgroup analysis suggested a possible survival benefit for cisplatin plus S-1 in the subset of patients with diffuse gastric cancer, there was a lack of superiority for cisplatin plus S-1 over cisplatin plus FU in a later randomized trial that focused specifically on diffuse gastric cancer [<a href="#rid175">175</a>].</p><p></p><p class="headingAnchor" id="H225803592"><span class="h4">Irinotecan-containing regimens</span><span class="headingEndMark"> — </span>Several trials have assessed the benefit of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> combined with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, fluoropyrimidines, or combinations of these drugs, but no superiority has been shown in phase III trials for any irinotecan-based regimen over a cisplatin-based triplet combination. Thus, irinotecan-based combinations cannot be considered to be preferable to a platinum-containing regimen for first-line therapy.</p><p><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a> has been combined with fluoropyrimidines, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>. In the previously described meta-analysis, the comparison of irinotecan-containing versus non-irinotecan-containing regimens (mainly FU/cisplatin) revealed a nonstatistically significant trend toward better survival with irinotecan (HR for death 0.86, 95% CI 0.73-1.02) [<a href="#rid176">176</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irinotecan</strong><strong> plus fluoropyrimidines or </strong><strong>cisplatin</strong> – The superiority of FOLFIRI  (<a class="graphic graphic_table graphicRef76300" href="/d/graphic/76300.html" rel="external">table 11</a>) over FU plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> with or without <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> was shown in a French randomized phase II trial involving 136 patients with advanced gastric cancer [<a href="#rid177">177</a>]. Compared with FU plus leucovorin alone or with cisplatin, the group receiving FOLFIRI had significantly higher response rates (40 versus 13 and 27 percent, respectively) and significantly longer median PFS (6.9 versus 3.2 and 4.9 months, respectively) and overall survival (11.3 versus 6.8 and 9.5 months, respectively). Roughly similar outcomes (response rates 42 to 44 percent, median survival 10 to 12 months) have been obtained using <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> in combination with oral <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> [<a href="#rid178">178-180</a>] and using irinotecan plus S-1 [<a href="#rid181">181</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is also active and well tolerated, particularly when administered weekly [<a href="#rid138">138,182-186</a>]. The superiority of cisplatin (80 mg/m<sup>2</sup> on day 1 every 28 days) plus irinotecan (70 mg/m<sup>2</sup> on days 1 and 15) as compared with infusional FU alone was shown in the phase III JCOG 9912 trial (described above) [<a href="#rid138">138</a>]. The response rate (38 versus 9 percent) and PFS (4.8 versus 2.9 months) were both significantly higher with cisplatin plus irinotecan. However, rates of grade 3 or 4 toxicity were also significantly higher (neutropenia [65 versus 1 percent], hyponatremia [23 versus 6 percent], anorexia [33 versus 13 percent], diarrhea [9 versus &lt;1 percent], and nausea [21 versus 7 percent]).</p><p></p><p class="bulletIndent1">Modest superiority of FOLFIRI over <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (ECX) was suggested in a French intergroup trial that randomly assigned 416 patients with previously untreated, advanced gastric or EGJ adenocarcinoma to FOLFIRI or ECX [<a href="#rid187">187</a>]. While there was a slight advantage in terms of time to treatment failure that favored FOLFIRI (5.1 versus 4.2 months), there were no significant differences in median PFS, overall survival, or response rates. Furthermore, while FOLFIRI was better tolerated overall (rate of grade 3 or 4 toxicity 69 versus 84 percent with ECX), the difference was only in hematologic adverse events (38 versus 65 percent); the rate of grade 3 or 4 nonhematologic adverse events was nearly identical (53 versus 54 percent).</p><p></p><p class="headingAnchor" id="H3510774204"><span class="h4">Triplet regimens</span><span class="headingEndMark"> — </span>We do not prefer triplet regimens over doublet regimens in patients receiving cytotoxic chemotherapy alone. In our view, these regimens are more toxic than a fluoropyrimidine plus platinum doublet, and they have not been shown to improve overall survival. (See <a class="local">'Is there an optimal combination regimen?'</a> below.)</p><p class="headingAnchor" id="H1678080692"><span class="h5">Epirubicin, cisplatin, and fluorouracil</span><span class="headingEndMark"> — </span>ECF  (<a class="graphic graphic_table graphicRef62502" href="/d/graphic/62502.html" rel="external">table 12</a>) was associated with a response rate of 71 percent in a report involving 128 patients with advanced disease [<a href="#rid188">188</a>]. In a subsequent randomized trial, 274 patients with advanced esophagogastric adenocarcinoma or undifferentiated cancer were randomly assigned to ECF or FU, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (FAMTX) [<a href="#rid5">5</a>]. ECF was associated with a superior response rate (45 versus 21 percent) and median survival (8.9 versus 5.7 months). ECF caused more alopecia and nausea, while FAMTX was associated with more hematologic toxicity and infections. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer"</a>.)</p><p>Newer regimens that combine short-term, high-dose infusional FU with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> modulation (eg, FOLFOX), or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> may be more effective than older regimens in which cisplatin was combined with bolus FU alone [<a href="#rid144">144,189-191</a>]. This has led to questions as to the contribution of the anthracycline to the efficacy of ECF:</p><p class="bulletIndent1"><span class="glyph">●</span>A report of the CALGB 80403 (Alliance) trial, a randomized phase II trial in which <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> was added to ECF, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, or FOLFOX, concluded that response rates, PFS, and median overall survival were comparable in the ECF and FOLFOX groups [<a href="#rid157">157</a>]. However, this trial included cetuximab in both arms, and it was neither designed nor intended as a noninferiority trial of FOLFOX versus ECF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An individual patient data meta-analysis of the Global Advanced/Adjuvant Stomach Tumor Research International Collaboration group concluded that there was no role for <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> in combination with a fluoropyrimidine and a platinum agent [<a href="#rid192">192</a>].</p><p></p><p>Thus, the contribution of the anthracycline and the benefit of ECF over other modern fluoropyrimidine-containing regimens (eg, FOLFOX, XELOX/CAPOX) remain unanswered questions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The REAL trial</strong> – The REAL trial was a landmark large randomized trial reported in 2008 that compared four different chemotherapy regimens in 1002 patients with advanced gastric cancer: ECF, ECX  (<a class="graphic graphic_table graphicRef53899" href="/d/graphic/53899.html" rel="external">table 13</a>), EOF, and EOX  (<a class="graphic graphic_table graphicRef75288" href="/d/graphic/75288.html" rel="external">table 14</a>) [<a href="#rid159">159</a>]. The study was sufficiently powered to demonstrate noninferiority. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer"</a>.)</p><p></p><p class="bulletIndent1">As noted above, this trial (and a second one) showed that outcomes were comparable when <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> was substituted for infusional FU in the ECF regimen, a finding that was reinforced in a subsequent meta-analysis of both trials. (See <a class="local">'Cisplatin plus a fluoropyrimidine'</a> above.)</p><p></p><p class="bulletIndent1">They also showed, as did the meta-analysis [<a href="#rid176">176</a>], that outcomes were comparable when <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> was substituted for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> in the ECF regimen. (See <a class="local">'Oxaliplatin combinations'</a> above.)</p><p></p><p class="headingAnchor" id="H24"><span class="h5">Docetaxel-containing</span><span class="headingEndMark"> — </span>Most (but not all [<a href="#rid193">193</a>]) <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> combinations with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, FU, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> are active in advanced gastric and gastroesophageal adenocarcinoma and esophageal SCC, but more toxic than doublet regimens [<a href="#rid194">194-208</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Docetaxel</strong><strong>, </strong><strong>cisplatin</strong><strong>, and FU (DCF) and modified DCF</strong> – The DCF (or TCF) regimen  (<a class="graphic graphic_table graphicRef73324" href="/d/graphic/73324.html" rel="external">table 15</a>) was compared with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus FU alone in the multinational TAX-325 trial, which enrolled 457 patients with chemotherapy-naïve advanced gastric cancer [<a href="#rid194">194</a>]. The group receiving <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> did significantly better in terms of response rate (37 versus 25 percent), time to tumor progression (5.6 versus 3.7 months), and two-year survival (18 versus 9 percent). The incidence of grade 3 or 4 diarrhea (20 versus 8 percent) and neutropenia (30 versus 14 percent) was higher with triplet therapy.</p><p></p><p class="bulletIndent1">Based on these results, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> was approved in the United States and Europe, in combination with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and FU, for the treatment of advanced gastric cancer. However, the contribution of cisplatin remains uncertain. Similar results (overall response rate 38 percent, median survival 9.5 months) are reported using docetaxel and infusional FU without cisplatin [<a href="#rid197">197</a>].</p><p></p><p class="bulletIndent1">A modified schedule of DCF is associated with preserved efficacy and improved tolerability  (<a class="graphic graphic_table graphicRef79612" href="/d/graphic/79612.html" rel="external">table 16</a>) [<a href="#rid209">209</a>]. In a randomized comparison of modified DCF (without prophylactic growth factor support) versus standard DCF (with growth factor support) in 85 patients with previously untreated, metastatic gastric adenocarcinoma, modified DCF was more efficacious (median overall survival 18.8 versus 12.6 months) and, even without growth factor support, less toxic [<a href="#rid210">210</a>]. (See  <a class="medical medical_review" href="/d/html/85680.html" rel="external">"Treatment protocols for esophagogastric cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Docetaxel</strong><strong>, </strong><strong>oxaliplatin</strong><strong>, and FU</strong> – <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a>, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, infusional FU, and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (FLOT) is a commonly used regimen in the neoadjuvant setting for gastric cancer. (See  <a class="medical medical_review" href="/d/html/2523.html" rel="external">"Adjuvant and neoadjuvant treatment of gastric cancer", section on 'FLOT'</a>.)</p><p></p><p class="bulletIndent1">At least two trials have explored the benefit of taxane-, fluoropyrimidine-, and oxaliplatin-containing triplet therapy compared with an oxaliplatin-containing doublet, and they have come to opposite conclusions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial, 143 patients aged 65 or older with locally advanced or metastatic esophagogastric cancer were randomly assigned to FOLFOX with or without <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> 50 mg/m<sup>2</sup> every two weeks [<a href="#rid156">156</a>]. There was a trend toward longer PFS with triplet therapy, but there was no difference in overall survival. Furthermore, triplet therapy was also associated with significantly worse toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the second randomized phase II trial, 248 patients with locally recurrent or metastatic gastric adenocarcinoma were randomly assigned to <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>; docetaxel, oxaliplatin, and FU (TEF); or docetaxel, oxaliplatin, and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (TEX) [<a href="#rid155">155</a>]. The TEF combination proved superior for objective response rate (46 versus 26 and 23 percent for TEX and docetaxel plus oxaliplatin, respectively) and median PFS (7.66 versus 5.55 and 4.50 months, respectively). The frequency and type of adverse events were similar across all three groups.</p><p></p><p class="headingAnchor" id="H1038702199"><span class="h4">Is there an optimal combination regimen?</span><span class="headingEndMark"> — </span>As noted above, there is no globally accepted first-line chemotherapy regimen for advanced, HER2-negative esophagogastric cancer, and practice is variable [<a href="#rid211">211</a>]. Although multiple trials have been conducted of different chemotherapy regimens for first-line therapy, direct comparisons (head-to-head phase III randomized trials) of many regimens are lacking. When multiple specific interventions are compared across trials, a network of studies can be established where all the studied interventions are linked to each other by individual trials. Network meta-analysis (also termed "mixed treatment comparison" or "multiple treatment comparison") evaluates all studies and all interventions simultaneously to produce multiple pairwise estimates of the relative effects of each intervention compared with every other intervention, allowing both direct and indirect comparisons to be made.</p><p>A network meta-analysis of first-line chemotherapy for advanced esophagogastric cancer that incorporated 17 different chemotherapy regimens with 37 direct comparisons for overall survival (50 trials, 10,249 patients) and PFS (34 trials, 7795 patients) came to the following conclusions combining direct and indirect effects [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All treatments resulted in better overall survival and PFS as compared with best supportive care alone, except for anthracycline monotherapy. Fluoropyrimidine- and non-cisplatin-containing doublets, fluoropyrimidine-cisplatin doublets, and all triplet regimens showed significant gains in overall survival compared with a fluoropyrimidine alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fluoropyrimidine doublet containing <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> significantly improved overall survival compared with a fluoropyrimidine plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (for a fluoropyrimidine plus irinotecan, the HR for death was 0.85, 95% CI 0.71-0.99; for a fluoropyrimidine plus oxaliplatin, the HR was 0.83, 95% CI 0.71-0.98). The cisplatin-fluoropyrimidine doublet was also associated with more grade 3 or 4 toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anthracycline-containing triplets (eg, ECF, EOX) and the docetaxel-containing triplet DCF showed no benefit over fluoropyrimidine doublets in either overall survival or PFS, and they were more toxic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A triplet regimen containing a fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, and a taxane (eg, TEX, TEF) significantly improved PFS (but not overall survival) when compared with a fluoropyrimidine doublet with a taxane (HR for progression 0.61, 95% CI 0.38-0.99), a fluoropyrimidine plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> (HR 0.62, 95% CI 0.38-0.99), and a fluoropyrimidine plus oxaliplatin (HR 0.67, 95% CI 0.44-0.99). Furthermore, the triplet regimen was more toxic than a fluoropyrimidine plus oxaliplatin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall, based on efficacy and toxicity, fluoropyrimidine doublets (a fluoropyrimidine plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, a fluoropyrimidine plus a taxane, or a fluoropyrimidine plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>) were preferred as first-line therapy over <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> doublets, anthracycline triplets, and DCF.</p><p></p><p class="headingAnchor" id="H3156476812"><span class="h3">Chemotherapy dosing in older and frail patients</span><span class="headingEndMark"> — </span>At least with the CAPOX regimen, dose attenuation does not compromise outcomes and that starting treatment with lower initial doses in frail/older individuals is a reasonable strategy. whether this general principle of dose-attenuated therapy applies to other chemotherapy regimens are both not clear.</p><p>Most trials of palliative chemotherapy have not included frail or older patients, and the benefits and risks of chemotherapy in these patients are less certain. At least some data suggest that lower initial chemotherapy doses provide noninferior cancer control and better tolerability in this setting.</p><p>Optimal chemotherapy dosing for the XELOX/CAPOX regimen was addressed in a trial in which 514 older/frail patients with advanced esophagogastric cancer, including SCC histology, with an adequate baseline comprehensive geriatric assessment, a glomerular filtration rate (GFR) ≥30 mL/min and a total bilirubin &lt;2 times the upper limit of normal (ULN) were randomly assigned to standard 21-day cycles of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (130 mg/m<sup>2</sup> on day 1) plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (625 mg/m<sup>2</sup> twice daily on days 1 to 21), the same regimen with 80 percent of the usual doses, or the same regimen with 60 percent of the usual doses [<a href="#rid212">212</a>]. All patients with a GFR of 30 to 50 mL/min or a total bilirubin of 1.5 to 2 times the ULN received 75 percent of the allocated capecitabine doses. Noninferiority of the lower-dose regimens was assessed primarily using PFS at 12 months, with a noninferiority boundary of 1.34. Patient experience during chemotherapy was assessed using overall treatment utility (OTU), a composite outcome based on clinician-assessed clinical benefit and patient-assessed tolerability, quality of life, and perceived satisfaction with treatment. A good OTU required clinical benefit as scored by the clinician plus patient satisfaction with treatment, no major toxicity, and no decline in quality of life. By contrast, a poor OTU required both a clinician score of "no benefit" and patient dissatisfaction with treatment, major toxicity or deterioration in quality of life, or patient death during treatment.</p><p>Overall, the lowest doses tested provided noninferior cancer control and the best patient experience (as assessed by the OTU, toxicity, and quality of life). Compared with standard doses, noninferiority was confirmed for both the 80 percent dose regimen (HR for PFS 1.09, 95% CI 0.89-1.32) and the 60 percent dose regimen (HR 1.10, 95% CI 0.90-1.33). Median overall survival was comparable in all three groups (7.5, 6.7, and 7.6 months, respectively). No subgroup (age, performance status, extent of frailty, baseline geriatric assessment) clearly benefited from higher-dose therapy. The study did not address whether clinicians should subsequently attempt dose escalation if initial doses of XELOX/CAPOX are tolerated.</p><p class="headingAnchor" id="H3177602527"><span class="h2">Investigational agents</span></p><p class="headingAnchor" id="H4229170044"><span class="h3">Zolbetuximab</span><span class="headingEndMark"> — </span>Zolbetuximab is an investigational monoclonal antibody that targets CLDN18.2, which is expressed by gastric and gastroesophageal cancer. In separate randomized placebo-controlled phase III trials (SPOTLIGHT and GLOW), the addition of zolbetuximab to oxaliplatin-based chemotherapy (either FOLFOX or CAPOX) improved PFS and OS in patients with previously untreated locally advanced or unresectable, HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma [<a href="#rid213">213,214</a>]. </p><p class="headingAnchor" id="H1172527843"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114875.html" rel="external">"Society guideline links: Gastric cancer"</a> and  <a class="medical medical_society_guidelines" href="/d/html/120117.html" rel="external">"Society guideline links: Esophageal cancer"</a>.)</p><p class="headingAnchor" id="H451367179"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16832.html" rel="external">"Patient education: Esophageal cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/83156.html" rel="external">"Patient education: Stomach cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2481177814"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General considerations</strong> – The goals of chemotherapy in patients with advanced esophagogastric cancer are symptom palliation, improved quality of life, and prolonged survival. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1">All patients should have a full assessment of symptom burden, and social supports prior to starting chemotherapy. Early referral and initiation of interdisciplinary and palliative care services improve outcomes. (See <a class="local">'Early supportive care'</a> above.)</p><p></p><p class="bulletIndent1">Biomarker assessment often determines choice of initial therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients with unresectable, locally advanced, recurrent, or metastatic gastric or esophageal adenocarcinoma who are potential candidates for <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> should have their tumors assayed for human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification using specific criteria developed for esophagogastric adenocarcinomas. (See <a class="local">'Assessment of HER2 status and selection of candidates for trastuzumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients regardless of histology should have their tumors assayed for deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H), and for overexpression of programmed cell death ligand 1 (PD-L1). (See <a class="local">'Choice of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment selection</strong> – Our general approach to first-line systemic therapy for metastatic esophagogastric cancer is based on biomarker expression and histology, as outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef129948" href="/d/graphic/129948.html" rel="external">algorithm 1</a>) and summarized below.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Squamous cell cancer (SCC)</strong> – For patients with advanced SCCs and high PD-L1 expression (TPS ≥1 percent or CPS ≥10), we suggest first-line therapy with chemotherapy plus immunotherapy rather than chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). </p><p></p><p class="bulletIndent2">For those whose tumors have low PD-L1 expression, we also suggest chemotherapy plus immunotherapy rather than chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) given the survival benefits in a meta-analysis. However, we have a lower threshold to omit or discontinue immunotherapy in this population due to unfavorable features, as the likelihood of benefit is lower in such patients. We do not favor immunotherapy alone due to concerns about early progression/death compared with chemotherapy alone. (See <a class="local">'Squamous cell cancers'</a> above.)</p><p></p><p class="bulletIndent2">Although the chemotherapy backbone in the CheckMate and KEYNOTE studies was <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU), we prefer <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in combination with an oxaliplatin-based regimen such as <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> with bolus plus short-term FU (FOLFOX,  (<a class="graphic graphic_table graphicRef109416" href="/d/graphic/109416.html" rel="external">table 17</a>)). Where available (mainly China), camrelizumab in combination with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and cisplatin is an appropriate alternative. (See <a class="local">'Selection of the chemotherapy backbone for combined therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adenocarcinoma</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>HER -overexpression</strong> – For patients with HER2-positive (3+ immunohistochemistry staining or in situ hybridization positivity) adenocarcinomas with no contraindication to <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, we suggest trastuzumab plus platinum-based chemotherapy rather than chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Assessment of HER2 status and selection of candidates for trastuzumab'</a> above and <a class="local">'Benefit of trastuzumab'</a> above.)</p><p></p><p class="bulletIndent3">We also suggest adding <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to initial <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> plus fluoropyrimidine- and platinum-based chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include pembrolizumab plus FOLFOX and trastuzumab  (<a class="graphic graphic_table graphicRef141603" href="/d/graphic/141603.html" rel="external">table 6</a>), and pembrolizumab plus CAPOX and trastuzumab  (<a class="graphic graphic_table graphicRef141602" href="/d/graphic/141602.html" rel="external">table 7</a>). (See <a class="local">'Adding pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent3">The optimal chemotherapy backbone for patients receiving <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> is not established. For most patients, we prefer FOLFOX  (<a class="graphic graphic_table graphicRef109416" href="/d/graphic/109416.html" rel="external">table 17</a>) or <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (XELOX/CAPOX  (<a class="graphic graphic_table graphicRef109415" href="/d/graphic/109415.html" rel="external">table 18</a>)).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>HER2-negative disease</strong> – For most patients with HER2-negative adenocarcinomas and CPS ≥10, we suggest the addition of either <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to an oxaliplatin-containing chemotherapy regimen (eg, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>) or XELOX/CAPOX  (<a class="graphic graphic_table graphicRef112347" href="/d/graphic/112347.html" rel="external">table 2</a>)) rather than systemic chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), as this approach improved overall survival in randomized trials. (See <a class="local">'High PD-L1 expression'</a> above.)</p><p></p><p class="bulletIndent3">For most patients with HER2-negative adenocarcinomas and CPS of 5 to 9, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus an oxaliplatin-containing chemotherapy regimen (eg, FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>) or XELOX/CAPOX  (<a class="graphic graphic_table graphicRef112347" href="/d/graphic/112347.html" rel="external">table 2</a>)) rather than systemic chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Intermediate PD-L1 expression'</a> above.)</p><p></p><p class="bulletIndent3">For patients with HER2-negative adenocarcinoma and CPS &lt;5, we suggest chemotherapy alone rather than immunotherapy plus chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Low or absent PD-L1 expression'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>dMMR/MSI-H</strong> – For patients with dMMR/MSI-H tumors, most of which express PD-L1, we suggest first-line immunotherapy rather than chemotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> monotherapy and immunotherapy plus systemic chemotherapy are both acceptable options in this setting. (See <a class="local">'Deficient mismatch repair'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No molecular marker or contraindication to targeted therapy</strong> – The benefits of immunotherapy for adenocarcinomas with no PD-L1 expression is uncertain. Although opinion differs, we suggest initial chemotherapy alone rather than immunotherapy plus chemotherapy in these patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Low or absent PD-L1 expression'</a> above.)</p><p></p><p class="bulletIndent3">The choice of regimen is empiric. In general, combination regimens provide higher response rates but only modestly longer disease control and survival. (See <a class="local">'Combination chemotherapy'</a> above.)</p><p></p><p class="bulletIndent3">For patients who are candidates for aggressive therapy, we suggest a fluoropyrimidine-containing doublet rather than a triplet regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For most patients, we prefer FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 1</a>), or XELOX/CAPOX  (<a class="graphic graphic_table graphicRef112347" href="/d/graphic/112347.html" rel="external">table 2</a>), or where available, S-1 plus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> other reasonable options include FU plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, or S-1 plus cisplatin. (See <a class="local">'Is there an optimal combination regimen?'</a> above and <a class="local">'Oxaliplatin combinations'</a> above and <a class="local">'Cisplatin plus a fluoropyrimidine'</a> above.)</p><p></p><p class="bulletIndent3">For older patients and those with a poor performance status or significant comorbidity, we would choose leucovorin-modulated FU alone or single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>. Other reasonable options are single-agent <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, low-dose weekly taxanes, or dose-attenuated XELOX/CAPOX. (See <a class="local">'Single-agent chemotherapy'</a> above and <a class="local">'Chemotherapy dosing in older and frail patients'</a> above.)</p><p></p><p class="headingAnchor" id="H1665044457"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Panos Fidias, MD, and Johanna Bendell, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">SEER Cancer Statistics http://www.seer.cancer.gov/statistics/ (Accessed on March 31, 2011).</li><li><a class="nounderline abstract_t">Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.</a></li><li><a class="nounderline abstract_t">Salvon-Harman JC, Cady B, Nikulasson S, et al. Shifting proportions of gastric adenocarcinomas. Arch Surg 1994; 129:381.</a></li><li><a class="nounderline abstract_t">Wijnhoven BP, Siersema PD, Hop WC, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 1999; 86:529.</a></li><li><a class="nounderline abstract_t">Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261.</a></li><li><a class="nounderline abstract_t">Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996.</a></li><li><a class="nounderline abstract_t">Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009; 20:885.</a></li><li><a class="nounderline abstract_t">Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007; 18:898.</a></li><li><a class="nounderline abstract_t">Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15:955.</a></li><li><a class="nounderline abstract_t">Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13:87.</a></li><li><a class="nounderline abstract_t">Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16:1826.</a></li><li><a class="nounderline abstract_t">Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998; 78:511.</a></li><li><a class="nounderline abstract_t">Wang K, Johnson A, Ali SM, et al. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist 2015; 20:1132.</a></li><li><a class="nounderline abstract_t">Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587.</a></li><li><a class="nounderline abstract_t">Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163.</a></li><li><a class="nounderline abstract_t">Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903.</a></li><li><a class="nounderline abstract_t">Ter Veer E, Haj Mohammad N, van Valkenhoef G, et al. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. J Natl Cancer Inst 2016; 108.</a></li><li><a class="nounderline abstract_t">Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8:CD004064.</a></li><li><a class="nounderline abstract_t">Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 2017; 11:CD004063.</a></li><li><a class="nounderline abstract_t">van Kleef JJ, Ter Veer E, van den Boorn HG, et al. Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst 2020; 112:12.</a></li><li><a class="nounderline abstract_t">Attar A, Malka D, Sabaté JM, et al. Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study. Nutr Cancer 2012; 64:535.</a></li><li><a class="nounderline abstract_t">Anandavadivelan P, Lagergren P. Cachexia in patients with oesophageal cancer. Nat Rev Clin Oncol 2016; 13:185.</a></li><li><a class="nounderline abstract_t">Kim GM, Kim SJ, Song SK, et al. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer 2017; 17:283.</a></li><li><a class="nounderline abstract_t">Arends J. Struggling with nutrition in patients with advanced cancer: nutrition and nourishment-focusing on metabolism and supportive care. Ann Oncol 2018; 29:ii27.</a></li><li><a class="nounderline abstract_t">Lu Z, Fang Y, Liu C, et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol 2021; 39:748.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.</a></li><li><a class="nounderline abstract_t">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.</a></li><li><a class="nounderline abstract_t">Park SR, Kim MJ, Nam BH, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer 2017; 83:32.</a></li><li><a class="nounderline abstract_t">Kulangara K, Zhang N, Corigliano E, et al. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Arch Pathol Lab Med 2019; 143:330.</a></li><li><a class="nounderline abstract_t">Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320.</a></li><li><a class="nounderline abstract_t">Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375.</a></li><li><a class="nounderline abstract_t">Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23.</a></li><li><a class="nounderline abstract_t">Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013; 31:4311.</a></li><li><a class="nounderline abstract_t">Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022; 386:449.</a></li><li class="breakAll">FDA List of cleared or approved companion diagnostic devices (in vitro and imaging tools) https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools (Accessed on February 15, 2022).</li><li><a class="nounderline abstract_t">Ahn S, Kim KM. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. Mod Pathol 2021; 34:1719.</a></li><li><a class="nounderline abstract_t">Zhou KI, Peterson B, Serritella A, et al. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clin Cancer Res 2020; 26:6453.</a></li><li><a class="nounderline abstract_t">Catenacci DVT, Moya S, Lomnicki S, et al. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov 2021; 11:308.</a></li><li><a class="nounderline abstract_t">Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398:27.</a></li><li><a class="nounderline abstract_t">Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022; 603:942.</a></li><li><a class="nounderline abstract_t">Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24:1181.</a></li><li class="breakAll">Updated US prescribing information for nivolumab available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s091lbl.pdf (Accessed on April 19, 2021).</li><li class="breakAll">https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo (Accessed on March 09, 2022).</li><li><a class="nounderline abstract_t">Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6:1571.</a></li><li><a class="nounderline abstract_t">Rha SY, Wyrwicz LS, Weber PEY, et al. VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Ann Oncol 2023.</a></li><li><a class="nounderline abstract_t">Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398:759.</a></li><li class="breakAll">FDA approves pembrolizumab for esophageal or GEJ carcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma?utm_medium=email&amp;utm_source=govdelivery (Accessed on March 23, 2021).</li><li class="breakAll">https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda (Accessed on March 09, 2022).</li><li><a class="nounderline abstract_t">Zhao JJ, Yap DWT, Chan YH, et al. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. J Clin Oncol 2022; 40:392.</a></li><li class="breakAll">Metges J-P, Kato K, Sun J-M, et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study (abstract). J Clin Oncol 2022.40.4_suppl.241. Abstract available online at https://meetinglibrary.asco.org/record/204509/abstract (Accessed on February 15, 2022).</li><li><a class="nounderline abstract_t">Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23:234.</a></li><li><a class="nounderline abstract_t">Yamashita K, Iwatsuki M, Harada K, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer 2020; 23:95.</a></li><li class="breakAll">Opdivo, INN-nivolumab. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (Accessed on June 15, 2022).</li><li><a class="nounderline abstract_t">Yoon HH, Dong H, Shi Q. Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise. Clin Cancer Res 2022; 28:3173.</a></li><li class="breakAll">OPDIVO- nivolumab injection, prescribing information. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394 (Accessed on June 15, 2022).</li><li class="breakAll">YERVOY- ipilimumab injection, prescribing information. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66 (Accessed on June 15, 2022).</li><li><a class="nounderline abstract_t">Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 2022; 377:e068714.</a></li><li><a class="nounderline abstract_t">Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 2022; 40:277.</a></li><li><a class="nounderline abstract_t">Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA 2021; 326:916.</a></li><li><a class="nounderline abstract_t">Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023; 24:483.</a></li><li><a class="nounderline abstract_t">Yap DWT, Leone AG, Wong NZH, et al. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups. JAMA Oncol 2023; 9:215.</a></li><li><a class="nounderline abstract_t">Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol 2022; 8:1456.</a></li><li><a class="nounderline abstract_t">Wu HX, Pan YQ, He Y, et al. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. J Clin Oncol 2023; 41:1735.</a></li><li><a class="nounderline abstract_t">Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol 2021; 7:895.</a></li><li><a class="nounderline abstract_t">Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43:413.</a></li><li><a class="nounderline abstract_t">Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100:487.</a></li><li><a class="nounderline abstract_t">Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98:833.</a></li><li><a class="nounderline abstract_t">Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8:363.</a></li><li><a class="nounderline abstract_t">Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687.</a></li><li><a class="nounderline abstract_t">Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18:2833.</a></li><li><a class="nounderline abstract_t">Koopman T, Smits MM, Louwen M, et al. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol 2015; 141:1343.</a></li><li><a class="nounderline abstract_t">Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273.</a></li><li><a class="nounderline abstract_t">Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523.</a></li><li><a class="nounderline abstract_t">Fornaro L, Vivaldi C, Parnofiello A, et al. Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. Br J Cancer 2019; 120:522.</a></li><li><a class="nounderline abstract_t">Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012; 18:546.</a></li><li><a class="nounderline abstract_t">Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010; 34:1868.</a></li><li><a class="nounderline abstract_t">Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011; 24:899.</a></li><li><a class="nounderline abstract_t">Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18:53.</a></li><li><a class="nounderline abstract_t">Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016; 140:1345.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015; 18:476.</a></li><li><a class="nounderline abstract_t">Ieni A, Barresi V, Giuffrè G, et al. HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. Oncol Lett 2013; 6:1591.</a></li><li><a class="nounderline abstract_t">Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797.</a></li><li><a class="nounderline abstract_t">Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457:299.</a></li><li><a class="nounderline abstract_t">Shah MA, Xu RH, Bang YJ, et al. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. J Clin Oncol 2017; 35:2558.</a></li><li><a class="nounderline abstract_t">Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 2018; 19:1372.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Ter Veer E, Creemers A, de Waal L, et al. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. Int J Cancer 2018; 143:438.</a></li><li><a class="nounderline abstract_t">Park H, Jin RU, Wang-Gillam A, et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2020; 6:1231.</a></li><li><a class="nounderline abstract_t">Chu MP, Hecht JR, Slamon D, et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol 2017; 3:767.</a></li><li><a class="nounderline abstract_t">Sun J, Ilich AI, Kim CA, et al. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. Clin Colorectal Cancer 2016; 15:257.</a></li><li><a class="nounderline abstract_t">Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 2020; 21:821.</a></li><li><a class="nounderline abstract_t">Lee CK, Rha SY, Kim HS, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun 2022; 13:6002.</a></li><li><a class="nounderline abstract_t">Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021; 600:727.</a></li><li class="breakAll">Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s132lbl.pdf (Accessed on April 03, 2023).</li><li><a class="nounderline abstract_t">Pectasides E, Stachler MD, Derks S, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 2018; 8:37.</a></li><li><a class="nounderline abstract_t">Chao J, Bedell V, Lee J, et al. Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. JAMA Netw Open 2020; 3:e203652.</a></li><li><a class="nounderline abstract_t">Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59:822.</a></li><li><a class="nounderline abstract_t">Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49:1448.</a></li><li><a class="nounderline abstract_t">Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016; 53:42.</a></li><li><a class="nounderline abstract_t">Warneke VS, Behrens HM, Böger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013; 24:725.</a></li><li><a class="nounderline abstract_t">Rüschoff J, Nagelmeier I, Baretton G, et al. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe 2010; 31:208.</a></li><li><a class="nounderline abstract_t">Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59:832.</a></li><li><a class="nounderline abstract_t">Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15:65.</a></li><li><a class="nounderline abstract_t">Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104:1372.</a></li><li><a class="nounderline abstract_t">Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013; 24:1754.</a></li><li><a class="nounderline abstract_t">Yoshida H, Yamamoto N, Taniguchi H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch 2014; 465:145.</a></li><li><a class="nounderline abstract_t">Wang YK, Chen Z, Yun T, et al. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma. World J Gastroenterol 2015; 21:4680.</a></li><li><a class="nounderline abstract_t">Prins MJ, Ruurda JP, van Diest PJ, et al. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol 2013; 24:1290.</a></li><li><a class="nounderline abstract_t">Haffner I, Schierle K, Raimúndez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol 2021; 39:1468.</a></li><li><a class="nounderline abstract_t">Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol 2016; 34:443.</a></li><li><a class="nounderline abstract_t">Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:490.</a></li><li><a class="nounderline abstract_t">Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119.</a></li><li><a class="nounderline abstract_t">Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18:5992.</a></li><li><a class="nounderline abstract_t">Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656.</a></li><li><a class="nounderline abstract_t">Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24:1253.</a></li><li><a class="nounderline abstract_t">Lordick F, Kang YK, Salman P, et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. J Clin Oncol 2013; 31S: ASCO #4021.</a></li><li><a class="nounderline abstract_t">Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012; 130:2845.</a></li><li><a class="nounderline abstract_t">Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000; 31:35.</a></li><li><a class="nounderline abstract_t">Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011; 18:2010.</a></li><li><a class="nounderline abstract_t">Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20:120.</a></li><li><a class="nounderline abstract_t">Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, et al. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. Br J Cancer 2017; 116:1526.</a></li><li><a class="nounderline abstract_t">Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86:1086.</a></li><li><a class="nounderline abstract_t">Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23:341.</a></li><li><a class="nounderline abstract_t">Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70:380.</a></li><li><a class="nounderline abstract_t">Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2011; 67:1265.</a></li><li><a class="nounderline abstract_t">Kii T, Takiuchi H, Gotoh M, et al. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho 2006; 33:621.</a></li><li><a class="nounderline abstract_t">Köhne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89:997.</a></li><li><a class="nounderline abstract_t">Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50:2218.</a></li><li><a class="nounderline abstract_t">Kok TC, van der Gaast A, Splinter TA. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Ann Oncol 1996; 7:533.</a></li><li><a class="nounderline abstract_t">Alberts AS, Schoeman L, Burger W, et al. A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus. Am J Clin Oncol 1992; 15:35.</a></li><li><a class="nounderline abstract_t">Hara H, Kadowaki S, Asayama M, et al. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Int J Clin Oncol 2018; 23:275.</a></li><li><a class="nounderline abstract_t">Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15:1344.</a></li><li><a class="nounderline abstract_t">Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64:232.</a></li><li><a class="nounderline abstract_t">Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548.</a></li><li><a class="nounderline abstract_t">van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18:2772.</a></li><li><a class="nounderline abstract_t">Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10:1063.</a></li><li><a class="nounderline abstract_t">Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99:584.</a></li><li><a class="nounderline abstract_t">Lee SJ, Cho SH, Yoon JY, et al. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Cancer Chemother Pharmacol 2009; 65:159.</a></li><li><a class="nounderline abstract_t">Jeung HC, Rha SY, Shin SJ, et al. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 2007; 97:458.</a></li><li><a class="nounderline abstract_t">Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215.</a></li><li><a class="nounderline abstract_t">Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014; 140:319.</a></li><li><a class="nounderline abstract_t">Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435.</a></li><li><a class="nounderline abstract_t">van Meerten E, Eskens FA, van Gameren EC, et al. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 2007; 96:1348.</a></li><li><a class="nounderline abstract_t">Louvet C, André T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543.</a></li><li><a class="nounderline abstract_t">Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658.</a></li><li><a class="nounderline abstract_t">Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:29.</a></li><li><a class="nounderline abstract_t">Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006; 94:959.</a></li><li><a class="nounderline abstract_t">Neri B, Pantaleo P, Giommoni E, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer 2007; 96:1043.</a></li><li><a class="nounderline abstract_t">Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008; 31:259.</a></li><li><a class="nounderline abstract_t">Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2007; 97:593.</a></li><li><a class="nounderline abstract_t">Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012; 48:518.</a></li><li><a class="nounderline abstract_t">Wang J, Chang J, Yu H, et al. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemother Pharmacol 2013; 71:905.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015; 26:149.</a></li><li><a class="nounderline abstract_t">Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer 2013; 49:835.</a></li><li><a class="nounderline abstract_t">Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol 2016; 34:2736.</a></li><li><a class="nounderline abstract_t">Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010; 28S: ASCO #4006.</a></li><li><a class="nounderline abstract_t">Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36.</a></li><li><a class="nounderline abstract_t">Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015; 26:141.</a></li><li><a class="nounderline abstract_t">Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21:1045.</a></li><li><a class="nounderline abstract_t">Xu R-H, Wang Z-Q, Shen L, et al. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial. J Clin Oncol 2019; 37S: ASCO #4017.</a></li><li><a class="nounderline abstract_t">Popov I, Radosevic-Jelic L, Jezdic S, et al. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J BUON 2008; 13:505.</a></li><li><a class="nounderline abstract_t">Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011; 14:50.</a></li><li><a class="nounderline abstract_t">Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33:1216.</a></li><li><a class="nounderline abstract_t">Warner E, Jensen JL, Cripps C, et al. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol 1999; 38:255.</a></li><li><a class="nounderline abstract_t">Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20:666.</a></li><li><a class="nounderline abstract_t">Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20:1529.</a></li><li><a class="nounderline abstract_t">Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol 2008; 26S:  ASCO #4533.</a></li><li><a class="nounderline abstract_t">Nishikawa K, Tsuburaya A, Yoshikawa T, et al. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Eur J Cancer 2018; 101:220.</a></li><li><a class="nounderline abstract_t">Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:663.</a></li><li><a class="nounderline abstract_t">Lenz HJ, Lee FC, Haller DG, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109:33.</a></li><li><a class="nounderline abstract_t">Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28:1547.</a></li><li><a class="nounderline abstract_t">Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013; 49:3616.</a></li><li><a class="nounderline abstract_t">Ajani JA, Abramov M, Bondarenko I, et al. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol 2017; 28:2142.</a></li><li><a class="nounderline abstract_t">Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; :CD004064.</a></li><li><a class="nounderline abstract_t">Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004; 22:4319.</a></li><li><a class="nounderline abstract_t">Oh SC, Sur HY, Sung HJ, et al. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br J Cancer 2007; 96:1514.</a></li><li><a class="nounderline abstract_t">Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010; 21:71.</a></li><li><a class="nounderline abstract_t">Luo HY, Wang ZQ, Wang FH, et al. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol 2011; 34:555.</a></li><li><a class="nounderline abstract_t">Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011; 14:72.</a></li><li><a class="nounderline abstract_t">Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004; 18:22.</a></li><li><a class="nounderline abstract_t">Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270.</a></li><li><a class="nounderline abstract_t">Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94:641.</a></li><li><a class="nounderline abstract_t">Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15:921.</a></li><li><a class="nounderline abstract_t">Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319.</a></li><li><a class="nounderline abstract_t">Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014; 32:3520.</a></li><li><a class="nounderline abstract_t">Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609.</a></li><li><a class="nounderline abstract_t">Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25:2580.</a></li><li><a class="nounderline abstract_t">Yun J, Lee J, Park SH, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010; 46:885.</a></li><li><a class="nounderline abstract_t">Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. J Clin Oncol 2008; 26S: ASCO #4512.</a></li><li><a class="nounderline abstract_t">GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 2013; 49:1565.</a></li><li><a class="nounderline abstract_t">Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4:501.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991.</a></li><li><a class="nounderline abstract_t">Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007; 25:3217.</a></li><li><a class="nounderline abstract_t">Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23:5660.</a></li><li><a class="nounderline abstract_t">Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23:494.</a></li><li><a class="nounderline abstract_t">Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 2010; 5:122.</a></li><li><a class="nounderline abstract_t">Park SR, Chun JH, Kim YW, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 2005; 28:433.</a></li><li><a class="nounderline abstract_t">Park SR, Chun JH, Yu MS, et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006; 94:1402.</a></li><li><a class="nounderline abstract_t">Giordano KF, Jatoi A, Stella PJ, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:652.</a></li><li><a class="nounderline abstract_t">Kim JG, Sohn SK, Kim DH, et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68:190.</a></li><li><a class="nounderline abstract_t">Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28:188.</a></li><li><a class="nounderline abstract_t">Overman MJ, Kazmi SM, Jhamb J, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010; 116:1446.</a></li><li><a class="nounderline abstract_t">Lorenzen S, Duyster J, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005; 92:2129.</a></li><li><a class="nounderline abstract_t">Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3205.</a></li><li><a class="nounderline abstract_t">Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3210.</a></li><li><a class="nounderline abstract_t">Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol 2009; 27S: ASCO #4512.</a></li><li><a class="nounderline abstract_t">Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29:868.</a></li><li><a class="nounderline abstract_t">Shah MA, Janjigian YY, Stoller R, et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol 2015; 33:3874.</a></li><li><a class="nounderline abstract_t">Dijksterhuis WPM, Verhoeven RHA, Slingerland M, et al. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. Int J Cancer 2020; 146:1889.</a></li><li><a class="nounderline abstract_t">Hall PS, Swinson D, Cairns DA, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:869.</a></li><li><a class="nounderline abstract_t">Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023; 401:1655.</a></li><li><a class="nounderline abstract_t">Xu R, Shitara K, Ajani JA, et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. J Clin Oncol 2023; 41;36S.</a></li></ol></div><div id="topicVersionRevision">Topic 2473 Version 125.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.seer.cancer.gov/statistics/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : SEER Cancer Statistics http://www.seer.cancer.gov/statistics/ (Accessed on March 31, 2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827707" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512326" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Shifting proportions of gastric adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215831" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996151" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956258" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164454" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351256" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15151954" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9013471" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586897" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716036" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26336083" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7533517" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093725" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782930" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27576566" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28850174" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chemotherapy for advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182797" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31251346" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22494155" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573424" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cachexia in patients with oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427439" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence and prognostic implications of psychological distress in patients with gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29741571" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Struggling with nutrition in patients with advanced cancer: nutrition and nourishment-focusing on metabolism and supportive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417481" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655437" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28711577" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30028179" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399552" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nivolumab in previously untreated melanoma without BRAF mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795410" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027431" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145345" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108470" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108470" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34002009" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32820017" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33234578" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34102137" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35322232" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37875143" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37875143" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37875143" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880601" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454674" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454674" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454674" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34860570" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34860570" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35030335" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451991" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451991" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35671005" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35671005" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35671005" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35440464" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35245446" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34519801" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37080222" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36480211" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36006624" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36473145" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33792646" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855114" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19156142" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948459" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061514" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20728210" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468783" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544671" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668283" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441328" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745584" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252257" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107094" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Expression of Her-2 in carcinomas of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460800" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169738" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : HER2 testing in gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27841667" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038874" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24260051" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422971" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Assessment of a HER2 scoring system for gastric cancer: results from a validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20665045" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28574779" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30217672" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30217672" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29451302" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469386" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737436" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803708" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437664" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36224176" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34912120" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34912120" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28978556" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338752" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092393" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146959" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26693898" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23139264" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Her2/neu testing in gastric cancer: evaluating the risk of sampling errors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20443098" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092394" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16328035" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21487407" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23524864" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24889042" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25914479" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23334118" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33764808" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26628478" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594786" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594787" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22565005" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22977193" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689179" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23233651" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21780108" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665910" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21267790" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143264" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28463962" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912736" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955859" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7914428" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20703479" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685160" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966415" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16416165" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8839912" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550077" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29039072" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319239" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697963" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862723" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894878" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19818685" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18665164" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479256" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17653073" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282805" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366758" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349393" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437008" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454110" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966088" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303863" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16552439" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353926" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525305" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667920" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243774" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370661" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416687" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23063354" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382098" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172173" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Capecitabine and oxaliplatin for advanced esophagogastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316259" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682457" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19145671" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21340667" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9301445" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227449" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153121" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474114" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30096702" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446338" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133415" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159816" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899532" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911091" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238327" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Chemotherapy for advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514373" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473829" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605504" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101386" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21340666" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685830" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506629" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857295" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060529" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458249" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25287828" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993836" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577037" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20060288" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352439" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31101534" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075117" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664469" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110025" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659494" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19898259" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199979" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641896" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497828" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16006756" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803015" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20108336" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942631" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664467" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664468" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21189380" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438119" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340065" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33983395" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37068504" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2−locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
